





# **ANTI-DOPING TUE Policy**

2025

# **CONTENTS**

ANTI-DOPING POLICY - TUE ARTICLE
ANTI-DOPING TUE POLICY
APPLYING FOR A TUE – A GUIDE FOR PLAYERS
ASTHMA MEDICATIONS
GLUCOCORTICOIDS
IV INFUSIONS
TREATMENTS REQUIRING A RETROSPECTIVE APPLICATION FOR A TUE
TREATMENTS REQUIRING A PROSPECTIVE APPLICATION FOR A TUE
HOW TO COMPLETE AND SUBMIT THE TUE FORM
ALREADY HAVE A TUE?
CRITERIA FOR GRANTING A TUE
DECLARING AND RENEWING A TUE
WHAT HAPPENS IF MY TUE APPLICATION IS TURNED DOWN?
EMERGENCY TREATMENT
DATA PROTECTION
DETERMINING THE TUE DURATION
TUE FORM PRIVACY NOTICE
TUE FORM
TUE FORM ADHD MEDICATIONS
ANTI-DOPING EVIDENCE (MEDICAL) FILE
DRUG INFORMATION WEBSITES











## **EXTRACT FROM EUROPEAN TOUR ANTI-DOPING POLICY 2025:**

## Therapeutic Use Exemptions ("TUEs")

*Players* may be granted a TUE for the use of a Prohibited Substance and/or Prohibited Method if (and only if), on the balance of probabilities, the following four criteria are fulfilled:

- 1. The Prohibited Substance or Prohibited Method in question is needed to treat a diagnosed medical condition supported by clinical evidence; and
- The therapeutic use of the Prohibited Substance or Prohibited Method will not, on the balance of
  probabilities, produce any additional enhancement of performance beyond what might be anticipated
  by a return to the Player's normal state of health following the treatment of a legitimate medical
  condition<sup>2</sup>; and
- 3. The Prohibited Substance or Prohibited Method is an indicated treatment for the medical condition, and there is no reasonable therapeutic alternative<sup>3</sup>; and
- 4. The necessity for the use of the otherwise Prohibited Substance or Prohibited Method is not a consequence, wholly or in part, of a prior use (without a TUE) of any substance or method which was prohibited at the time of such use.

## A TUE can only be granted if all four criteria are fulfilled.

An application (including all requested medical information) for a TUE shall be made to the PGA EUROPEAN TOUR at least **thirty (30) days prior** to participation in the PGA EUROPEAN TOUR co-sponsored, approved or coordinated tournament for which the TUE is sought, unless it is an emergency or exceptional situation.

#### **TUE APPLICATION PROCESS**

A TUE application will be considered by an independent TUE Committee appointed and administered by the PGA EUROPEAN TOUR, who may seek the guidance of additional specialists as appropriate from an established list of medical experts<sup>4</sup>. The TUE Committee decides if a TUE application presents sufficient justification for the granting of a TUE.

A *Player* whose TUE application is denied by the TUE Committee may appeal the denial to a TUE Appeal Committee by submitting a written appeal to the PGA EUROPEAN TOUR within fourteen (14) days of the date of Notification of the denial. In considering the appeal, the TUE Appeal Committee may consult with additional medical advisors and may require the Player to submit additional information. Within thirty (30) days of receiving the TUE appeal, the PGA EUROPEAN TOUR will advise the *Player* of the TUE Appeal Committee's decision either confirming the denial of the TUE or granting the TUE. The TUE Appeal Committee's decision on the TUE is final and binding.

Prior to a TUE being granted, a *Player* who uses a substance on the PGA EUROPEAN TOUR Prohibited List does so at his own risk of a TUE denial, potentially resulting in a violation under the Policy. The PGA European Tour may recognise TUEs granted by other golf organisations provided the exemption was granted in a manner consistent with the PGA European Tour's Policy.

<sup>&</sup>lt;sup>1</sup> The Use of the Prohibited Substance or Prohibited Method may be part of a necessary diagnostic investigation rather than a treatment per se.

<sup>&</sup>lt;sup>2</sup> A Player's normal state of health will be determined on an individual basis. A normal state of health for a specific Player is their state of health but for the medical condition for which the Player is seeking the TUE.

<sup>&</sup>lt;sup>3</sup> The Physician must explain why the treatment chosen was the most appropriate, e.g., based on experience, side-effect profiles or other medical justifications, including, where applicable, geographically specific medical practice, and the ability to access the medication. Further, it is not always necessary to try and fail alternatives before using the Prohibited Substance or Prohibited Method. 
<sup>4</sup> European Tour has established an independent Therapeutic Use Exemption Committee (TUEC) to consider applications for the grant or recognition of TUEs, consistent with the relevant international standard as outlined in PGAET TUE Policy.

In order to obtain approval for a TUE, a player must have a well documented medical condition supported by reliable and relevant medical data. A TUE is essential for all long term prohibited medication use, and for prohibited medication prescribed during a tournament.

#### **RETROACTIVE TUE**

A Retroactive TUE may be applied for if any of the following apply:

- a. Emergency or urgent treatment was necessary.
- b. Exceptional circumstances prevented the Player from submitting a TUE application prior to *Sample* collection (The Player is required to explain the exceptional circumstances that prevented a prospective TUE application)
- c. The Player has prepared a *Medical File* to submit as a TUE application, for a medically justified and specified treatment, as permitted under the TUE Policy.

#### **DECLARATION OF MEDICATIONS AT TIME OF TESTING:**

At the time of an Anti-Doping Test, Players are requested to declare Medications (and Supplements) taken within the last 7-10 days. Note some medications are detectable for 60 days or longer. It is in a Player's interests to declare all medications (even up to two months) and provide details and the prescriber. Follow up enquiries may be necessary to help explain a presumptive analytical finding.

#### **ANTI-DOPING RULE VIOLATION and TUE**

The presence of a Prohibited Substance or its Metabolites or Markers, Use or Attempted Use of a Prohibited Substance or Prohibited Method, Possession of a Prohibited Substance or Prohibited Method or administration of a Prohibited Substance or Prohibited Method consistent with the provisions of an applicable TUE shall not be considered an Anti-Doping Rule Violation.

The Anti-Doping Administrator will review TUE decisions and Medical Files submitted to explain an Adverse Analytical Finding, if consistent with an applicable TUE, the AAF shall not be considered an Anti-Doping Rule Violation.

**NOTE:** Possession of an illegal substance may be considered a criminal offence. Check before you travel. TUE evidence may help explain medically justified treatments.

WARNING: Tampering or attempted tampering with medical evidence, including TUE applications or Medical File information may be considered an Anti-Doping Rule Violation. All amendments must be recorded contemporaneously by the person responsible for providing original evidence.

#### **MEDICAL FILE**

A Medical File is the primary information in a TUE application and would simply require the Player to sign additional data consent section of the TUE Form to confirm agreement to process via the TUE Committee.

A Medical File may be completed to record any medication or supplement used, with additional information [including photographs of the medication prescription, supplement batch numbers, research results, messages and emails]. The Medical File may be updated with additional information at any time, as version history is retained.

Short term treatments using a Prohibited medication out of competition should be recorded by the Player using a Medical File which may be submitted as supporting evidence in the event of an Adverse Finding from a Doping Control test. If in doubt, complete and submit a Medical File.

Players are responsible for retaining medical records and other information that may be required to explain an adverse or atypical finding.

## ANTI-DOPING TUE POLICY

## 1. INTRODUCTION

Players, like anyone else, may have illnesses or conditions that require the use of a substance or method on the European Tour Prohibited List. In such a case, a Therapeutic Use Exemption (TUE) <u>may</u> under strict conditions, provide a Player with authorisation to use (or possess) a medication or method while continuing to play.

TUEs provide exemptions for athletes to use and possess substances or methods that are on the Prohibited List. Players and their treating medical personnel should first verify if there is even a need for a TUE. To clarify, if a substance or method is not prohibited, then no TUE is necessary.

Players (who remain responsible for obtaining a TUE) should check if the substance is prohibited using relevant drug information websites listed in on the final page of this document, or consulting the Tour's permitted list for 2025. (The Prohibited List is **not recommended** as a way to confirm the status of a medication, it is a list of examples only). If advice is sought from the Tour's Anti-Doping or Medical Team, request this advice in writing and retain a copy of this advice.

## 2. EUROPEAN TOUR ANTI-DOPING TUE POLICY

A Player who needs to use a Prohibited Substance or Prohibited Method for therapeutic reasons must apply for and obtain a TUE prior to using or possessing the substance or method in question, unless the Player is entitled to apply for a TUE retroactively as set out in Section 4; in both cases, all criteria set out in Section 3 TUE conditions must be satisfied.

**Policy Principle:** A TUE is required for the use of all prohibited medications or methods, supported by reliable and relevant medical evidence. A Medical File is the record of diagnosis, medical evidence and prescribing physician's data. Upon review by the Anti-Doping Administrator, a TUE (or valid Medical File), if consistent with an Adverse Analytical Finding, is not an Anti-Doping Rule Violation.

**Comment:** There may be situations where a Player has a medical condition and is Using or Possessing a Prohibited Substance or Prohibited Method prior to becoming subject to anti-doping rules. In that case, such prior Use/Possession does not require a TUE and a retrospective TUE application, if approved, will be sufficient.

**NOTE:** For Professional Golf, the Prohibited List applies at all times, in and out of competition. Consequently, where indicated in this Policy, a Player should apply for and obtain a TUE where appropriate. There are specific circumstances when short term treatments, particularly for emergency or urgent treatment, with insufficient time to apply for a TUE, as indicated in this Policy, that a retroactive application may be submitted.

In such cases Players are strongly advised to have a **Medical File** prepared and ready to demonstrate they satisfy the TUE Conditions, in case an application for a retroactive TUE is necessary. This seeks to address situations where for Therapeutic reasons, a Player uses a substance out of competition short term, although there is a risk the substance will remain in their system in-competition. In such situations The PGA European Tour permits the Player to apply for a retroactive TUE where the Player has not applied in advance.

Players should verify if the substance or method they are using, or in possession of, is legal in the specific jurisdiction (e.g., country, state, or province) where they compete or plan to compete. A TUE only grants permission to use and/or possess a prohibited substance or method while competing in sport. For example, cannabis, CBD or opioids are illegal in various states and

countries and there may be serious legal consequences for transgressing those rules regardless of whether one was granted a TUE.

A Player who returns an Adverse Analytical Finding, is allowed the opportunity to apply for a retroactive TUE for the legitimate medical use of the prohibited substance in question (where the athlete has not applied in advance).

An example is the short-term use of glucocorticoids (GCs) out-of-competition. In-competition use of a Prohibited Substance requires a TUE application.

#### 3. CONDITIONS FOR GRANTING A TUE

*Players* may be granted a TUE for the use of a Prohibited Substance and/or Prohibited Method if (and only if), on the balance of probabilities, the following four criteria are fulfilled:

- 1. The Prohibited Substance or Prohibited Method in question is needed to treat a diagnosed medical condition supported by clinical evidence;<sup>5</sup> and
- 2. The therapeutic use of the Prohibited Substance or Prohibited Method will not, on the balance of probabilities, produce any additional enhancement of performance beyond what might be anticipated by a return to the Player's normal state of health following the treatment of a legitimate medical condition<sup>6</sup>; and
- 3. The Prohibited Substance or Prohibited Method is an indicated treatment for the medical condition, and there is no reasonable therapeutic alternative<sup>7</sup>; and
- 4. The necessity for the use of the otherwise Prohibited Substance or Prohibited Method is not a consequence, wholly or in part, of a prior use (without a TUE) of any substance or method which was prohibited at the time of such use.

A TUE can only be granted if all four criteria are fulfilled.

WADA documents titled **TUE Physician Guidelines** available on WADA's website should be used to assist in the application of these criteria in relation to particular medical conditions. Granting of a TUE is based solely on consideration of the conditions set out in this section, it does not consider whether this is the most clinically appropriate or safe, or whether its use is legal in all jurisdictions.

## 4. RETROACTIVE TUE APPLICATION

A Retroactive TUE provides a Player with the opportunity to apply for a TUE for a Prohibited Substance or Prohibited Method after using or possessing the substance or method in question.

A Player may apply retrospectively for a TUE is any one of the following exceptions applies:

- a. Emergency or urgent treatment was necessary.
- b. Exceptional circumstances prevented the Player from submitting a TUE application prior to Sample collection such as insufficient time, opportunity or other exceptional circumstances

<sup>&</sup>lt;sup>5</sup> The Use of the Prohibited Substance or Prohibited Method may be part of a necessary diagnostic investigation rather than a treatment per se.

<sup>&</sup>lt;sup>6</sup> A Player's normal state of health will be determined on an individual basis. A normal state of health for a specific Player is their state of health but for the medical condition for which the Player is seeking the TUE.

<sup>&</sup>lt;sup>7</sup> The Physician must explain why the treatment chosen was the most appropriate, e.g., based on experience, side-effect profiles or other medical justifications, including, where applicable, geographically specific medical practice, and the ability to access the medication. Further, it is not always necessary to try and fail alternatives before using the Prohibited Substance or Prohibited Method.

prevented the Player from submitting an application for a TUE prior to Sample Collection. (The Player is required to explain the exceptional circumstances that prevented a prospective TUE application)

c. The Player has prepared a *Medical File* to submit as a TUE application, for a medically justified and specified treatment, as permitted under the TUE Policy. This may be relevant where the Player is using a short-term treatment of a Prohibited Substance or Method out of competition, (particularly for emergency or urgent treatment) although there is a risk the substance will remain in their system in-competition.

In exceptional circumstances, a Player may apply for retroactive approval, if it would be manifestly unfair not to grant a Player's application, (as determined by the Anti-Doping Administrator).

## 5. VALIDITY OF A TUE

A TUE granted by the TUE Committee appointed by the PGA European Tour is valid for period of time designated on the Certificate. The TUEC assigns a start and end date to each TUE, upon which the TUE will expire automatically. The TUEC should use the WADA TUE Physician Guidelines to guide them in determining the duration. Players need to be aware of the duration of their TUE and be ready to re-apply well in advance before it expires. The TUE may specify certain requirements (e.g., dosage). A TUE may be cancelled prior to its expiry if the athlete does not comply with any of the requirements or conditions imposed by the TUEC when it granted the TUE. For example, a TUEC may permit the use of testosterone under strict conditions, which may include submitting updated clinical test results to the Anti-Doping Administrator.

## **6. RENEWING A TUE**

Although not all tests or evaluations need necessarily be repeated, TUEs cannot be renewed without a new medical consultation and confirmation. The Player must complete a new application signed by their physician. The Player should reapply for the new TUE well in advance to allow sufficient time for a decision to be made on the application before the existing TUE expires. Automatic extension of a TUE is not allowed under any circumstances. It may not be necessary to have an extensive re-evaluation, particularly for long-standing conditions. However, this is on a case-by-case basis and the Player is advised to provide updated information rather than a brief note from a physician stating that the Player should continue treatment. Although the Player may receive a notification about an expiring TUE, it remains their responsibility to be aware and apply for a renewal of their TUE, when necessary.

# **TUE APPLICATION FORM OR MEDICAL FILE?**

The TUE form may be downloaded from the Player Portal area:

https://playerportal.europeantourgroup.com >INFORMATION HUB/ >Integrity Tab

Copies are also available through the Anti-Doping Adviser, Medical Team or via the Tournament Office. Use the PGA European Tour TUE form to make an application for a Therapeutic Use Exemption. A TUE form for ADHD treatment applications is available.

A Medical File, which is an online version of the TUE form completed and retained by the Player (or submitted for review to the CMO or ADA), yet available to update with subsequent treatments and medical evidence (including photographs of prescriptions, physician's professional qualifications) whilst retaining the audit trail of information as supporting evidence for retroactive application for a TUE.

This is an important record which may be necessary to explain (and possibly excuse) an Adverse Analytical Finding following the collection of a Sample by an anti-doping organisation.

## **APPLYING FOR A TUE - A Guide for Players**

## When to submit a TUE

If no alternative permitted medication is available for your medical condition and the medication your physician prescribes is prohibited, then you should submit a TUE application with all supporting medical evidence, (including the physician's diagnosis and professional information) promptly, if possible prior to commencing the medication. If in doubt, check with the CMO or ADA or submit for review.

In emergency and life-threatening situations, you should receive the necessary treatment and submit the TUE retrospectively. A Medical File may be completed to capture all information in anticipation of submitting a retroactive TUE Application (or submitted for review).

An application for a TUE should be submitted for all prohibited medications, when permitted alternatives have been tried, or if the prohibited substance is the only option available for the medical condition.

**Documentation Required:** The TUE Application Form must be answered completely and data sharing consent given. Information submitted should be sufficient to allow the TUE Committee to render a reasoned decision. Supporting medical evidence, including the following documents (copies of original reports) must be provided in support of a TUE request:

- Diagnosis, all evidence confirming the diagnosis,
- A comprehensive medical history, all condition specific requested records,
- Results of all relevant examinations, laboratory investigations and imaging studies, relevant to application (additional relevant investigations, examinations or imaging studies requested by TUE Committee will be undertaken at the cost of the applicant.
- In the case of non-demonstrable conditions, independent supporting medical opinion may be required in support of the application.

Guidance and checklists for treating physicians on the specific requirements for various medical conditions may be obtained from the World Anti-Doping Agency website. (Details below and on page 22/23)

## **TUE Physician Guidelines for various medical conditions:**



https://www.wada-

ama.org/en/search?q=TUE%20Physician%20Guidelines&filters%5Bcontent\_type%5D%5B%5D=%22resource%22

## TUE Checklists for different medical conditions



https://www.wada-

 $\underline{ama.org/en/search?q=Checklists\%20 for\%20 TUE\%20 Applications\&filters\%5B content\_type\%5D\%5B\%5D=\%22 resourc\\ \underline{e\%22}$ 

## **ASTHMA MEDICATIONS - TUE Information**

Asthma treatments include a range of treatments, some of which are prohibited; some are restricted and should be used carefully to avoid mistakenly overusing the medicine, which could lead to a positive test. If you require an asthma medication, you should be aware of how the anti-doping rules may impact upon you. Should your asthma condition require use in excess of the permitted limits, contact the European Tour Chief Medical Officer or Anti-Doping Adviser immediately. Complete a Medical File to record use. Check your asthma medication below:

## **ASTHMA MEDICATION CHECK LIST 2025:**

## **PERMITTED (By Inhalation only)**

## BETA<sub>2</sub>AGONISTS:

**Salbutamol/ Albuterol** (e.g., Ventolin, Respigen) - Permitted but with intake limited to a maximum of **1600 micrograms over 24 hours** but not to exceed **600** micrograms over **8 hours** starting from any dose.

Salbutamol inhalers commonly dispense either 100 or 200 micrograms per puff/inhalation, this relates to either 3 or 6 inhalations per 8-hour period. Check with your doctor the dosage of your inhaler.

Salmeterol (e.g., Serevent)

-Inhaled salmeterol, maximum 200 micrograms over 24 hours.

Formoterol (e.g., Oxis, Foradil, Symbicort)

- Permitted by inhalation maximum delivered dose 54 micrograms in divided doses not to exceed 36 micrograms over 12 hours starting from any dose.

**Vilanterol** (e.g., Relvar Ellipta) Permitted up to manufacturer's maximum recommended dose; expressed as the metered dose of 25 micrograms equivalent to delivered dose of 22 mcg.

Threshold is not valid in the presence of diuretics. If you are using a diuretic, you must have a Therapeutic Use Exemption to use both the diuretic and asthma medication. Refer to your doctor.

GLUCOCORTICOIDS: (e.g., Becotide, Beclazone, Budesonide, Flixotide, Pulmicort)

Other permitted asthma medications: Montelukast, Atrovent

## **PROHIBITED**

Other beta2 agonists, for example:

Terbutaline (e.g., Bricanyl) Bambuterol (e.g., Bambec)

US brands x Utibron or Arcapta (indacterol), Stiolto or Striverdi (olodaterol), Maxair (pirbuterol)

Oral Salbutamol (e.g., Ventolin in syrup form)

Nebulised Salbutamol.

#### Beta2Agonists-

Prohibited levels by inhalation: Presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Player proves, through a controlled pharmacokinetic study, that the abnormal result was the consequences of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

**Glucocorticoids** by oral/tablet, or by injection require an approved TUE.

BETA<sub>2</sub>AGONISTS: formoterol, salbutamol, salmeterol and vilanterol <u>by inhalation</u> are permitted when used in accordance with maximum dosage within 12/24 hours according to therapeutic regime.

For other beta₂agonists by inhalation, e.g., terbutaline, a medical file containing specified medical evidence is required to support your TUE application.

Multiple/Combination use of beta 2 agonists should be notified to the Anti-Doping Administrator/CMO.

**GLUCOCORTICOIDS** - Glucocorticoids by inhalation, e.g., Becotide, beclomethasone, Flixotide, fluticasone are **permitted**.

For some asthma medications, the application requires a more detailed medical file of specific information. You should ask your physician to prepare this medical file and be ready to submit this on request for independent review.

A Medical File may be reviewed by the European Tour Anti-Doping programme at any time.

For any oral glucocorticosteroid (tablet), a TUE application should be submitted and approval is required. A TUE certificate is required, for example if you are tested and an approved TUE could explain the Adverse Analytical Finding.

## GLUCOCORTICOIDS FOR OTHER MEDICAL CONDITIONS (e.g., Allergy or Injury)

NOTE: as of 1 January 2022 – all injectable routes of glucocorticoids are prohibited and subject to strict TUE approval criteria. To manage this change, complete a Medical File or TUE application for all injections for glucocorticoids at the time of treatment.

Depending on the timing of treatment and your next competition, you may need to submit a TUE application for treatment during a competition period. Otherwise, your Medical File may be held by you, or submitted for processing, if appropriate, for example to explain an Adverse Analytical Finding.

Medical File applications received will be reviewed and processed as applicable.

Glucocorticoids by oral, intravenous, intramuscular (for example to treat hay fever, Crohn's disease or arthritis) or rectal routes **require a TUE**. Submit an application on the TUE form accompanied by supporting medical evidence from the prescribing physician.

Short term Glucocorticoid treatments by non-systemic routes, for injury i.e., localised injection, (intraarticular, peritendinous, epidural, intradermal), require completion of a Medical File for treatments received out of competition (**or TUE Form if treatment is administered in -competition**), supported by diagnostic information and evidence regarding the choice of treatment using a prohibited substance, especially where permitted alternatives exist.

Topical glucocorticoids (e.g., eye drops, nasal sprays, creams & ointments) containing glucocorticoids are **permitted and do not require a TUE.** 

## **IV INFUSIONS**



From 1 January 2018, the permitted volume and timing of intravenous infusions of (**permitted**) substances changed to no more than a total of 100 mL per 12-hour period, except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

More specifically, IV infusions and/or injections of any substance in excess of 100 mL per 12-hour period are prohibited at all times, except for those legitimately received in the course of hospital treatments, surgical procedures, or clinical diagnostic investigations.

IV infusions or injections received in a medical practitioner's office, IV clinic or medical facility at a golf course are prohibited and require a TUE to cover use. Complete a Medical File and notify AD Adviser/CMO as a TUE application may be required

Note: permitted IV infusions have changed from "hospital admissions" to "hospital treatments," and "clinical investigations" to "clinical diagnostic investigations."

If a **prohibited** substance is administered intravenously or via injection, a TUE is necessary for this substance regardless of whether the infusion or injection is less than 100mL.

Hospital treatment includes treatment or admission at a physical hospital named as such. TUEs are still required for infusions provided through on-site event medical services, ambulatory treatment, outpatient clinics, doctors' or medical offices, home visits, etc.

**NOTE:** Non-medicinal IV infusions, for well-being, supplementation, hangover 'cure', or when oral rehydration is a practical alternative, or boosting are **NOT PERMITTED.** 

Clinical trials, or academic or private research projects are not clinical diagnostic investigations and are NOT PERMITTED

## **HOSPITAL/EMERGENCY ROOM VISIT**



Ensure a copy of the drugs chart and treatment record is obtained <u>prior</u> to being discharged. Any delay in obtaining records subsequently may impact eligibility to compete.

Check status of medications/treatment methods. If a TUE is required submit a TUE Form and copies of all medical records relating to treatment as soon as possible, If in doubt, complete and hold a Medical File. Share with CMO or ADA to assist your declaration of medications.

## TREATMENTS REQUIRING A RETROSPECTIVE APPLICATION FOR A TUE



Adrenaline Auto-Injector e.g., EpiPen, Emerade, Jext: Adrenaline; if you experience a severe allergic reaction and use an EpiPen or adrenaline injection, your Medical File/TUE application must be submitted within 3 days after use.

<u>Intravenous or Oral Narcotics</u>: Strong pain relief administered in the course of surgery may include prohibited narcotic drugs such as Fentanyl, Morphine. Submit your Medical File/TUE application, if your treatment is received <u>within 7 days</u> of your next golf tournament. Retain your Medical File in case required.

Intravenous, Injectable or Oral Glucocorticoids: IV, injection or oral Glucocorticoids used to treat hay fever, asthma, infections, and acute back pain, in addition to a range of inflammatory conditions. Corticosteroid tablets (for example prednisolone), intraarticular (IA), intramuscular (IM) and Intravenous (IV), or rectal administration are prohibited, at all times, IN or OUT of competition.

Treatment received or ongoing during the competition period (from registration to the end of the tournament play) requires you to submit a TUE. If you are prescribed a corticosteroid treatment in tablet, injection or rectal form, a TUE application must be completed, and submitted immediately prior to commencement of treatment.

In an emergency, a retrospective application for urgent treatment must be submitted immediately. Submit your TUE application within 7 days of last treatment.

<u>Blood Transfusions, Intravenous Diuretics & Masking Agents</u>: Submit a retrospective TUE as soon as practical after the procedure and <u>within 7 days</u> of last treatment.

NOTE: diuretics as eyedrops should be recorded on a Medical File. Declare dosage/use at time of testing.

## TREATMENTS REQUIRING A PROSPECTIVE (ADVANCE) APPLICATION FOR A TUE

## ADHD:

To assist with the detailed information required for TUE applications for **ADHD** conditions, a specific form is available to complete.

Please use this form when applying for ADHD medications which are prohibited.

## **DIABETES**:

Review the TUE Physician Guidelines and Checklist for Diabetes, and complete a TUE Form. It is important to ensure that the physician has correctly completed all the medical information, diagnosis, and medication details sections in the TUE application. It is also important that they sign and date the physician declaration.

## HOW TO COMPLETE AND SUBMIT THE TUE FORM

To apply, complete the relevant TUE form (available from the Player Portal) and obtain supporting evidence from your physician. If you have already obtained a TUE approval certificate through your national body, you should submit details of the application and certificate to the Tour ADA/Chief Medical Officer.

It is the Player's responsibility to submit a completed form.

The application form should **NOT** be submitted to the European Tour office. **Submit your TUE Application to antidoping@europeantourgroup.com** 

One form is required per medical condition even if the medical condition requires several medications.

**Note:** where a medical file is required to support a TUE application, this file should be submitted with the TUE form or after the TUE form has been submitted, to provide the detailed medical information retrospectively. It should be available on request, as it may be required to explain an adverse analytical finding if you are tested.

If your Physician requires further guidance on the status of medications, details of permitted medications and information for drug information websites to allow you and your physician to check the status of medications under the European Tour Anti-Doping Policy. The European Tour has adopted the WADA list of prohibited substances and <u>applies the full list across the Tour Schedule</u>, i.e., there is no distinction between in and out of competition time during the Tour. Additional information will be available to assist the completion of the TUE Form.

#### **ALREADY HAVE A TUE?**

If you already hold a previous approval from a National Anti-Doping Organisation or golf federation, **submit this evidence**. The PGA European Tour may, at its sole discretion, recognise TUEs granted by other golf organisations provided the TUE was granted in a manner consistent with the PGA European Tour's policy.

## **TUE Application Process**

Completed forms should be submitted as soon as the need for a prohibited substance in a medication is identified. Password protect documents containing sensitive personal information submitted.

The TUE Application will be reviewed, the next stage is to refer the TUE application to the independent TUE Committee or to hold for retrospective consideration. The Player will be advised of the status of the application.

What happens next? An application for a TUE which requires the review of a committee of independent medical experts to consider a full Therapeutic Use Exemption will be submitted to the TUE Committee as soon as there is sufficient medical evidence to support the application. The process for assessing each application is based on the International Standard for Therapeutic Use Exemptions to provide fair and consistent standards for the approval for use of a prohibited medication and may take up to 14 days to conclude. Players should bear this in mind when applying for approval in advance of a golf event.

The TUEC decision will be notified in writing. If the application is approved a certificate will be issued, indicating validity dates and specific treatment approved. If selected for testing at an ET or other golf event, declare the existence of a TUE on the Doping Control Form.

**NOTE:** If, after the TUE is granted, you require a materially different dosage, frequency, route of administration or duration or change of the treatment containing a Prohibited Substance and/or Method.

seek advice as to whether a new TUE application is required. The fact that a TUE exists will not prevent an Adverse Analytical Finding being considered an Anti-Doping Rule Violation.

## Criteria for Granting a TUE

Each TUE application is reviewed against four criteria:

- 1. The Prohibited Substance or Prohibited Method in question is needed to treat a diagnosed medical condition supported by clinical evidence;<sup>8</sup> and
- The therapeutic use of the Prohibited Substance or Prohibited Method will not, on the balance
  of probabilities, produce any additional enhancement of performance beyond what might be
  anticipated by a return to the Player's normal state of health following the treatment of a
  legitimate medical condition<sup>9</sup>; and
- 3. The Prohibited Substance or Prohibited Method is an indicated treatment for the medical condition, and there is no reasonable therapeutic alternative<sup>10</sup>; and
- 4. The necessity for the use of the otherwise Prohibited Substance or Prohibited Method is not a consequence, wholly or in part, of a prior use (without a TUE) of any substance or method which was prohibited at the time of such use.

A TUE can only be granted if all four criteria are fulfilled.

If all four criteria are met, the TUEC decision should be made within 14 days.

## **DECLARING AND RENEWING A TUE**

If selected for testing at an ET or other golf event, declare your medication or the TUE/Medical File on the Doping Control Form. There is no need to declare your medical condition.

TUE certificates have a specified time limit. Automatic renewal for ongoing conditions may be obtainable and will depend upon the medical condition. TUEs cannot be renewed without a new medical consultation and confirmation of the request by the Player's physician with appropriate supporting documentation. Changes to medication, even for the same medical condition will require a new TUE Application.

The PGA European Tour will recognise TUEs approved by other Tours when determined in accordance with the PGA European Tour's policy.

Please note, acceptance of Tour approved TUEs by National Anti-Doping Organisations is not guaranteed. You may be required to apply to your NADO (particularly when part of the IGF/NADO Registered Testing Pool.


**Guidance for Prescribing Physician:** Evidence should be as objective as possible in the clinical circumstances. In the case of non-demonstrable conditions independent supporting medical opinion will assist the application. If a permitted medication could be used to treat the medical condition, provide clinical justification as to why a permitted alternative is not appropriate.

The TUE Committee will decide if the application presents sufficient justification for the granting of a TUE.

<sup>&</sup>lt;sup>8</sup> The Use of the Prohibited Substance or Prohibited Method may be part of a necessary diagnostic investigation rather than a treatment per se.

<sup>&</sup>lt;sup>9</sup> A Player's normal state of health will be determined on an individual basis. A normal state of health for a specific Player is their state of health but for the medical condition for which the Player is seeking the TUE.

<sup>&</sup>lt;sup>10</sup> The Physician must explain why the treatment chosen was the most appropriate, e.g., based on experience, side-effect profiles or other medical justifications, including, where applicable, geographically specific medical practice, and the ability to access the medication. Further, it is not always necessary to try and fail alternatives before using the Prohibited Substance or Prohibited Method.



## WHAT HAPPENS IF MY TUE APPLICATION IS TURNED DOWN?

If your application is denied following a review by the TUEC, you are entitled to appeal this decision. If you wish to appeal the decision, you must lodge written notice of the appeal with the PGA European Tour's Anti-Doping Administrator within fourteen (14) days of receiving the decision. You should specify the grounds for the appeal and submit any further evidence in support of your application. An appeal committee, made up of three new medical experts, will be set up. The TUE Appeal Committee's decision is final and binding.

#### **EMERGENCY TREATMENT**

In an emergency you may submit an application for a TUE retrospectively where emergency treatment or treatment of an acute medical condition was necessary or in exceptional circumstances there was insufficient time or opportunity to submit, or for the TUEC to consider, an application for a TUE prior to you being tested. You should not assume that by submitting an emergency TUE application, that it will be granted. Use of or possession of a Prohibited Substance or Method before a TUE has been granted shall be entirely at your own risk. However, your declaration and application will be taken into consideration in deciding if there has been any anti-doping rule violation.

You may accept an emergency treatment. Check with the European Tour Anti-Doping Adviser or Chief Medical Officer, as soon as possible after treatment, whether you will need to apply for a TUE.

Many strong pain killers contain narcotics which are not permitted but can be taken in an emergency under doctor's instructions, but a TUE application should be submitted if treatment received within **7** days of your participation in a golf tournament.

If you receive emergency treatment e.g. (surgery or emergency admission to hospital), this may include prohibited drugs or methods. Obtain a copy of your treatment plan/drugs chart prior to being discharged. There may be a delay if you request this afterwards. Talk with your physician about your treatment plan.

Always check the status of ingredients of any IV infusion or injection, regardless of volume.

## ADVERSE FINIDNG INVESTIGATION

The Anti-Doping Administrator will review TUE decisions and Medical Files submitted to explain an Adverse Analytical Finding, if consistent with an applicable TUE, the AAF shall not be considered an Anti-Doping Rule Violation.

#### **DATA PROTECTION**

When you sign the TUE form you are consenting to the release of personal medical information to the PGA European Tour Anti-Doping Adviser and TUEC for the purposes of a review of that information only. All TUE information is handled in the strictest confidence and in accordance with current Data Protection laws.

If required to explain an Adverse Analytical Finding, anonymised information may be submitted to the accredited laboratory for review.

NOTE TUE information is retained for 10 years in accordance with the anti-doping protocol. Your data is not shared outside the anti-doping programme unless you consent.

You should read the Privacy Notice carefully to ensure you understand your rights and responsibilities as well as those of the designated recipients of your information.

**RETENTION POLICY;** To protect Players from retrospective investigations of treatments involving Prohibited Substances that conclude whether an Anti-Doping Rule Violation has been committed, Medical File/TUE applications shall be retained for a period of minimum 12 months and maximum 10 years.

## **DETERMINING THE TUE DURATION**

TUE duration is decided on a case-by-case basis although the TUE Physician Guidelines provides recommendations in this area. Below is a summary of recommendations from the Guidelines.

MEDICAL CONDITION	SUBSTANCES / METHOD	RECOMMENDED DURATIONS		
		12 months for a new diagnosis.		
ADHD	Stimulants – e.g., methylphenidate	Up to 4 years for those with a diagnosis made more than 12 months previously on a stable dose of medication.		
Adrenal Insufficiency Primary	Glucocorticoids	10 years in case of primary insufficiency, pituitary disease, or surgery		
Adrenal Insufficiency Secondary	Glucocorticoids	4-12 weeks		
	Stimulants and glucocorticoids:	Most patients respond to 1-2 doses.		
Anaphylaxis	Epinephrine (adrenaline)     Systemic     glucocorticoids:     hydrocortisone or     methylprednisolone	TUE for epinephrine for athletes at risk of future anaphylaxis; up to 5 years but notify every time use		
Androgen Deficiency / Male Hypogonadism – Primary or Secondary	Testosterone or human Chorionic Gonadotropin (hCG)	4 years but regular monitoring by ADO imperative		
Asthma	Beta-2 agonists     Glucocorticoids	Beta-2 agonists: 4 years Glucocorticoids: up to 12 months		
Cardiovascular Conditions: Arterial	1. Diuretics	Up to 4 years for arterial hypertension		
Hypertension	2. Beta-blockers	Up to 10 years for congenital LQTS		
Diabetes Mellitus - Type 1	Insulin	First granted TUE should not exceed a 1-year duration. All future TUEs can have a validity of up to 10 years		
Female-to-Male (FtM) Transgender Athletes	Testosterone	10 years		
Growth Hormone Deficiency (adult)	hGH	10 years if genetic, congenital, or hypothalamic- pituitary structural abnormality		
		years if due to brain trauma or irradiation  10 years if genetic, congenital, or hypothalamic-		
Growth Hormone		pituitary structural abnormality		
Deficiency (child & adolescent)	hGH	4 years if due to brain trauma or irradiation		
		For athletes transitioning into adulthood, the duration must be applicable to the situation		
Infertility / Polycystic Ovarian Syndrome (PCO)	<ol> <li>Clomiphene</li> <li>Spironolactone</li> </ol>	Infertility: 2 years PCO: 10 years		
Inflammatory Bowel Disease	Glucocorticoids	4 years		
Intravenous Infusion	Administration of i.v. fluids	Single medical episode		
Intrinsic Sleep Disorders	Stimulants e.g., Modafinil, methylphenidate and dexamphetamine	4 years with annual review by a specialist physician		
		Both GC and narcotics should be as short as possible, days to weeks.		
Musculoskeletal Conditions	Glucocorticoids     Narcotics	There are certain cases of chronic pain where duration of glucocorticoids and narcotics may be longer.		
Pain Management	Narcotics     Cannabinoids	Acute pain: (e.g. post-op) a period of days to a week		
Renal Transplantation	Glucocorticoids     Beta-Blockers     Diuretics     Erythropoietin (EPO)	Chronic pain: 1 to 4 years  10 years (if on EPO, regular monitoring of blood parameters & specialist review)		



#### STRICTLY CONFIDENTIAL

## **GUIDELINES FOR THE COMPLETION OF THE TUE FORM**

Please complete all sections in English, in capital letters or typing. Please note that information submitted in other languages may take longer to process due to the need for accurate translation. USE ONE FORM PER MEDICAL CONDITION.
You may complete this form online, then save the document and send it by email as an attachment. Password protect any TUE documentation sent by emails. Original signatures may be requested later. Failure to submit personal information with sufficient safeguards on data transfer shall be at Player's own risk

Complete all sections with as much information as possible, ask prescribing physician to complete section 4.

- 1. Player Information It is essential to have contact details, to check information and to advise the player of the TUEC decision.
- 2. Explain the relevant medical condition and the category of medication prescribed to treat this condition.
  - > WHAT is to be taken, full name of medication including ingredients
  - > HOW MUCH the dose. e.g., Number/quantity of tablets, injections etc
  - HOW it is being taken the route of administration, e.g. tablets, injections,
  - HOW OFTEN how many times a day/week, or if once only.
- Diagnostic information must be provided to support the application, e.g. blood tests, X rays, MRI scans, details of symptoms. Explain if a permitted medication is available and why it has not been used. Explain the duration of treatment and date it commenced.
- 4. Physician to complete declaration and contact details. Electronic completion is acceptable.
- 5. Complete if this is a retroactive application for emergency treatment or due to exceptional circumstances and explain why
- 6. Explain if a previous application has been made or if an existing TUE in place, (if so, attach a copy)
- 7. Player should read this section carefully, sign and date. Electronic completion is acceptable

#### **EXAMPLE OF MEDICAL EVIDENCE FILE**

## For ASTHMATICS - BETA2AGONISTS BY INHALATION

Except SALBUTAMOL by inhalation (maximum 1600 mcg over 24 hours, not to exceed 600 mcg over 8 hours).

SALMETEROL by inhalation (maximum 200 mcg over 24 hours).

FORMOTEROL by inhalation (maximum 54 micrograms over 24 hours).

VILANTEROL by inhalation (maximum 25 micrograms over 24 hours

ALL OTHER BETA<sub>2</sub>AGONISTS (e.g. terbutaline) require a TUE. Complete this form & prepare a medical file The following information must be recorded in a medical file, reviewed annually, and available to European Tour on request

- 1. A complete medical history
- 2. A comprehensive report of the clinical examination with specific focus on the respiratory system
- 3. A report of spirometry with the measure of the Forced Expiratory Volume in 1 second (FEV1)
- 4. If airway obstruction is present, the spirometry will be repeated after inhalation of a short-acting Beta2 agonist to demonstrate the reversibility of bronchoconstriction
- In the absence of reversible airway obstruction, a bronchial provocation test is required to establish the presence of airway hyper-responsiveness
- 6. Exact name, speciality, address (including telephone, e-mail, fax) of the examining physician

## For GLUCOCORTICOIDS by injection, oral or rectal administration

Supporting medical evidence required for the Use of Glucocorticoids by certain routes of administration

- by injection, (complete this form & attach additional medical evidence), intravenous, intramuscular, intra-articular, local, dermal
- by oral (tablet) or rectal administration (complete this form & attach additional medical evidence)
- > dermatological (skin cream), nasal (nose drops or sprays), eye (ointment or drops) or inhalation are PERMITTED


TUE Checklists by medical condition is available to assist you complete your TUE application. Check the Player Portal, Integrity Tab, Anti-Doping resources for Checklists documents or enter search term "Checklist" on: <a href="https://www.wada-ama.org">https://www.wada-ama.org</a>.


YOU MAY COMPLETE THIS FORM AND HOLD AS A MEDICAL FILE – SUBMIT AS YOUR TUE APPLICATION IF REQUESTED For assistance with completing this form, please contact Michele Verroken (ET Anti-Doping Administrator) +44(0)7785 326569 or by e-mail: <a href="mailto:(mverroken@consultant.etghq.com">(mverroken@consultant.etghq.com</a>) Or Dr Andrew Murray ET Chief Medical Officer +44 7791303980 or by email: <a href="mailto:Amurray@etghq.com">(murray@etghq.com</a>)

Complete online, save and send as an attachment, or print and fax.

Submit the completed form with supporting evidence by email to <a href="mailto:antidoping@europeantourgroup.com">antidoping@europeantourgroup.com</a>
Incomplete applications will be returned and should be resubmitted. Keep a copy of this application for your own records

Page 5 of 5






5. RETROACTIVE A	PPLICAT	ION				
Is this a retroactive application?	No Y	res 🔲	If Yes, d	ate treatment sta	rted	_dd/mm/yy_
Duration of treatment						2007
Indicate reason for retroactive appl  Emergency treatment or urgent treatment		at a constraint from				
Advance application not required un EMERGENCY treatment including nebulised salbutamol, IV diuretics Due to other exceptional circumstan	nder applicable g intravenous, or & masking age nces, insufficien	rules (e.g., El ral narcotics, nts, apply as it time or oppo	MERGENCY us IV or oral gluco soon as possibl ortunity to subm	e of adrenaline for a corticoids, apply with e after treatment). It application prior to	in 7 days of treatr sample collection	nent, or blood transfusions, (explain)
Where possible submit a prospe	ctive applicat	ion for use	of a Prohibit	ed Substance to	reduce risk of	a violation
6. PREVIOUS TUE AF	PLICAT	ION/AP	PROVE	TUE IN PL	ACE	
Have you submitted a previous T	UE application	on for the m	nedical condi	tion above?	No Yes	
If Yes, for which substance(s)						
To Whom?		When?		Decision:	Not Appro	
"if approved what duration does the app	roval have			ate approval en	ds	_dd/mm/yy
Attach copy of TUE Certificate of App	proval for same	e Prohibited	Substance.			
7. PLAYER'S DECLARA	TION and	DATA P	RIVACY	ONSENT		
I, certify that the committee and authorised officials obligations)	orise release	of my pers	onal medical	information to the	independent T	al to use the medication herapeutic Use Exempt r contractual confidentia
I consent to my physician(s) relea	soine to the c	shows poroco	ne(a) any rola	ant health inform	ation doomed	nonnenn to consider s
determine my application. I unders • used to evaluate my TUE request	tand and agre	e that my T	UE data (or pa	art of it) will only be	90	
<ul> <li>collected by the European Tour A this data. The Anti-Doping and correcipients in accordance with current</li> </ul>	ore Medical Te	eam shall s	tore, process	shall be principal and manage my	ly responsible fo data, including	or ensuring the protection its disclosure to authoris
<ul> <li>shared with other independent n administer TUE information proces applicable, in accordance with curre</li> </ul>	ssing) and all	necessary	staff involved	in the managem	ent, review or	appeal of TUE decisions
I understand and accept that recipie I reside. In some countries data pro	nts of my infor otection and p	rmation and rivacy laws	of the decision may not be ed	on this application on the one of t	n may be locate of my country of	d outside the country who residence.
Information will be stored securely used in conformity with my consen applicable laws in relation to my TU	it, I can file a	complaint w	vith my nation	al data protection	regulator. I ma	elieve my information is y have certain rights un-
I understand if I ever wish to obtain revoke this authorisation, I must re practitioner in writing of that fact. I investigations or procedures under	notify the Eur understand th	opean Tour at information	r Anti-Dopina	Adviser (myerroke	en@consultant.e	taha.com) and my medi
I have read and understood the TU accept its terms. By signing this for						ith my TUE Application a
				D	ate dd	mm/yy
Player's Signature				or guardian shall sign t		ehalf of the applicant 'mm/yx
If applicant is under 18 years of age or has a	Sign					
If applicant is under 18 years of age or has a	Sigi					
Player's Signature If applicant is under 18 years of age or has a Parent's/Guardian's Name	Sigi					

# **TUE FORM – ADHD Medication**

USE ONE FORM PER MEDICAL CONDITION  PLAYER PERSONAL INFORMATION  First Name(s)  Jack of Birth	Guidance for completion of this for Prescribing Phys This form may be completed online	sician information require e, saved as a document i	d to complete section emailed as an atta	ns 2, 3, 4, 5 chment, marked as confidential.
Testing Name    Control	USE	ONE FORM PER MED		
Address a complete applications will be information and about the superior from the complete applications will be information and about the superior from the complete applications will be information and about the superior from the complete applications will be information and about the superior from the complete applications will be information and about the superior from the complete applications will be information and about the superior from the complete from the complete applications will be information and about the superior from the complete applications will be information and about the approval ends and about the complete from the complete from the complete applications will be information and about the complete from the complete applications will be information and about the complete from the complete applications will be information and about the complete from the complete applications will be information and about the complete from the complete from the complete from the complete from the complete applications will be information and about the results of the complete from the compl		ION	First Name(s)	
Telephone of the complete certifiers and some attachment, or print and face.  Some include application of Treatment  Administration  Administr	ate of Birth ationality	dd/mm/yy	Unique ID/ Me	mbership No
Treatment and the complete continues and the complete continues and the complete continues applications with the complete of firm by weard to another property of the complete continues applications with the returned and allowed be required for the special of the complete continues applications with the returned and allowed to the property of the control of property of the complete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues applications with the complete of firm by weard to analyze deplete continues and the continues of posteriors and continues applications and allowed to be accordant to an advantage of the continues of posteriors and continues and analyze deplete applications. A propr	ity			
RELEVANT MEDICAL CONDITION & MEDICATION DETAILS area to for relevant founce fellow to indicate the types of medication you are declaring or applying for exemption.  RELEVANT MEDICAL CONDITION  ADHD  See A funite of Administration  Administration  Administration  Relevant Medication Include generic names & ingredients  Conce Only Emergency or Duration (Day/ Week/ Month)  The manage of Medication Include generic names & ingredients  Conce Only Emergency or Duration (Day/ Week/ Month)  The manage of the concept of the Copyan Administration  Administration  Administration  Frequency/Duration of Treatment  and an administration  Complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  The complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online, save and send as an attachment, or print and fax.  Solution the complete online of the complete onl	el (with iternational code)		Cell/ Mobile (wi international code	ith )
ADAD    Complete continues and send as an attachment, or print and fax. Solution the complete continues and send as an attachment, or print and fax. Solution the complete continues and send and send send send send send send send se		n:	Email 🔲	SMS Tel
ADAD    Complete continues and send as an attachment, or print and fax. Solution the complete continues and send as an attachment, or print and fax. Solution the complete continues and send and send send send send send send send se	RELEVANT MEDICAL CONDITION	N & MEDICATION DE	TAII S	
Trequest approval to use the information set out above is accurate.  I request approval to use the information set out above is accurate.  I request approval to use the medication for fire personal medication for the representation for the propersion of the proposal of	ase tick relevant boxes below to indicate	the types of medication	you are declaring or	applying for exemption
Intended Duration of Treatment  and treatment commenced	ELEVANT MEDICAL CONDITION	ADHD		
Intended Duration of Treatment    Intended Duration of Treatment	ull name of Medication nclude generic names & ingredien	Dose / units of administration	Route of Administration	Frequency/Duration of Treatmen
Intended Duration of Treatment    Intended Duration of Treatment			_	_
Interest of medications may be checked through drug information vebatiles lated in EL Anti-Disping information bissochook (N.B. Sulf stat at all. edge) calling kinche Verneine T. And-Disping deministration on 44 (0) 7785 328 596 or by email amountain disposability of the very state of the county of the completed form by email amountain disposability of the very state of the county of the cou	_			_
tended Duration of Treatment  deforming.  der Complete contine, save and send as an attachment, or print and fax.  Something the property of the applications will be returned and should be page 1 of 4. Kong a carry of the applications will be returned and should be page 1 of 4. Kong a carry of the application for year own records.  Transcriptory of the applications will be returned and should be page 1 of 4. Kong a carry of the application for year own records.  Transcriptory of the applications will be returned and should be page 1 of 4. Kong a carry of the application for year own records.  Transcriptory of the applications will be returned and should be page 1 of 4. Kong a carry of the application for year own records.  Transcriptory of the application for year own records.  PLAYER'S DECLARATION and DATA PRIVACY CONSENT  I request approved by that the information set out above is accurate.  I request approved out oue the medication for therapeutic purposes only. I authorise release of my personal medical information to the independent Therapeutic Use Exemption Committee and authorises release of my personal medical information to the independent Therapeutic by the European Tour.  I consent to my physician(s) releasing to the above person(s) any relevant health information deemed necessary to consider and deleasing violation in the context of potential and coping rule violation investigations and procedures.  I collected by the European Tour Anti-Doping and one Medical Team shall store, process and manage my data, including its disclosure to authorised recipients in acc	·			
The control of the process and manager of data. The Arth-Doping and core Medical Team shall above to the process of the proces	ntended Duration of Treatment			
that of medications may be checked through drug information websites lated in EL Aris Oping Information Herothook (N.B. Full list at al. ac)  valing Michael Varnolene ET Aris Doping Administrator on 144 (f) 7785 376 599 or by email management/consultant elabation or or hereful acceleration of the Aris Michael Varnolene ET Aris Doping Administrator on 144 (f) 7785 376 599 or by email management/consultant elabation or or hereful acceleration of the Aris Michael Varnolene ET Aris Doping Administrator or 144 (f) 7785 376 599 or by email management/consultant elabation or or hereful acceleration of the Aris Michael Varnolene Et Aris Aris Michael Varnolene Et Aris			eek/ Month)	
Complete online, save and send as an attachment, or print and fax.  Submit the completed form by email to entideding @unepearburgroup.com  Incomplete applications will be returned and should be resulted the resulted in the print of the pri	ss) by calling Michele Verroken ET Anti-Doping Ad	dministrator on +44 (0) 7785	326 569 or by email <u>m</u>	verroken@consultant.etghq.com or
when? Detailors: Not Approved Appr growed with duration does the approval have Date approval ends Appr growed what duration does the approval have Date approval ends Appr growed with duration does the approval for asme Prohibited Substance.  PLAYER'S DECLARATION and DATA PRIVACY CONSENT  I equest approval to use the medication for therapentic purposes only. I authorise release of my personal medical information to the independent Therapeutic Use Exemption Committee and authorises release of my personal medical information to the independent Therapeutic Use Exemption Committee and authorises of the appropriate and authorises of the appropriate and authorises of the appropriate the appropriate of the appropri				De WORLD Metablisses LEGINOS: G4D
than copy of TUE Certificate of Approval for same Prohibited Substance.  PLAYER'S DECLARATION and DATA PRIVACY CONSENT  I request approval to use the medication for therapeutic purposes only. I authorise release of my personal medical information to the independent Therapeutic Use Exemption Committee and authorise release of my personal medical information to the independent Therapeutic Use Exemption Committee and authorised release of my personal medical information to the independent Therapeutic Use Exemption Committee and authorised release of my personal medical information to the independent release of the properties of the control of the	STRICTLY CONFIDENTIAL			TOUR TOUR TOUR
I request approval to use the medication for therapeutic purposes only. I authorise release of my personal medical information to the independent Therapeutic purposes only. I authorise release of my personal medical information to the independent Therapeutic purposes only. I authorise release of my personal medical information to the independent release of the personal procession of the personal	Yes, for which substance(s)	When?	aba Decisio	n: Not Approved Approve
I request approval to use the medication for therapeutic purposes only. I authorise release of my personal medical information to the independent Therapeutic Use European Cournities and authorised oritions yet to professional or contractual confidentially obligations), appointed by the European Tour.  I consent to my physicanicy in leadings in the above person(s) any relevant health information deemed necessary to consider and determine my application.  I understand and agree that my TUE data (or port of it) will only be:  - used to evaluate my TUE request and in the context of potential and-doping rule violation investigations and grocodures.  - used to evaluate my TUE request and in the context of potential and-doping rule violation investigations and grocodures.  - collected by the European Tour Anti-Doping and core Medical Team who shall be principally responsible for ensuring the protection of this data. The Anti-Doping and core Medical Team shall store, process and manage my data, including its disclosure to authorised recipients in accordance with current data protection against the principally responsible for ensuring the protection of this data. The Anti-Doping and core Medical Team shall store, process and manage my data, including its disclosure to authorised recipients in accordance with current data protection against an experiment of TUE docisions if applicable, in accordance with current data protection legislation and where relevant in reduced, protected formation.  I understand and accept that recipients of my information and of the decision on this application may be located outside the country where I reside. In some countries data protection and privacy laws may not be equivalent to those of my country of residence.  Information with part barded personal protection in the protection in the protection registration in a protection in the protection of the formation in accordate data.  I understand if I ever wish to obtain more information about the use of my health information, to access, rect	Yes, for which substance(s)  O Whom?  If approved what duration does the approval he	ave	aba Decisio	n: Not Approved Approve
I request approval to use the medication for therapeutic purposes only. I authorise release of my personal medical information to the independent Therapeutic Use European Cournities and authorised oritions yet to professional or contractual confidentially obligations), appointed by the European Tour.  I consent to my physicanicy in leadings in the above person(s) any relevant health information deemed necessary to consider and determine my application.  I understand and agree that my TUE data (or port of it) will only be:  - used to evaluate my TUE request and in the context of potential and-doping rule violation investigations and grocodures.  - used to evaluate my TUE request and in the context of potential and-doping rule violation investigations and grocodures.  - collected by the European Tour Anti-Doping and core Medical Team who shall be principally responsible for ensuring the protection of this data. The Anti-Doping and core Medical Team shall store, process and manage my data, including its disclosure to authorised recipients in accordance with current data protection against the principally responsible for ensuring the protection of this data. The Anti-Doping and core Medical Team shall store, process and manage my data, including its disclosure to authorised recipients in accordance with current data protection against an experiment of TUE docisions if applicable, in accordance with current data protection legislation and where relevant in reduced, protected formation.  I understand and accept that recipients of my information and of the decision on this application may be located outside the country where I reside. In some countries data protection and privacy laws may not be equivalent to those of my country of residence.  Information with part barded personal protection in the protection in the protection registration in a protection in the protection of the formation in accordate data.  I understand if I ever wish to obtain more information about the use of my health information, to access, rect	Yes, for which substance(s) To Whom?  If approved what duration does the approval has tach copy of TUE Certificate of Approval for s	ave Prohibited Substance.	Decision Date approve	n: Not Approved Approve
Londont to my physician(s) relaxating to the above person(s) any relevant health information deemed necessary to consider and determine my application.  Lindocratoral and agrice that my TLE data (or port of it) will only be:  - used to evaluate my TLE request and in the context of potential and-doping rule violation investigations and procedures.  - used to evaluate my TLE request and in the context of potential and-doping rule violation investigations and procedures.  - collected by the European Tour Ant-Doping and core Medical Team who shall be principally responsible for ensuring the protection of this data. The Anti-Doping and core Medical Team who shall store, process and manage my data, including its disclosure to authorised recipents in accordance with current data protection legislation.  - shared with other independent medical and/or scientific experts (including the appointed TUE Committee, World Sports and who are applicable, in accordance with current data protection legislation and where relevant in resided, protection replaced in the country where I reside. In some countries data protection and privacy laws may not be equivalent to those of my information is not used in conformity with my consent. I can file a complaint with my national data protection regulator. If legislation is not used in conformity with my consent, I can file a complaint with my national data protection regulator. If understand if I ever wish to obtain more information in the file and the substan	Yes, for which substance(s) o Whom?    approved what duration does the approval he tach copy of TUE Certificate of Approval for a	ave Prohibited Substance.	Decision Date approve	n: Not Approved Approve
Lunderstand and agree that my TUE data (er part of ti) will only be:  used to evaluate my TUE request and in the context of potential ant-doping rule violation investigations and procedures;  collected by the European Tour Anti-Doping and core Medical Team shall store; process and manage my data, including its disclosure to authorised requests in a consciouse with current data prefected in spatial store; process and manage my data, including its disclosure to authorised requests in a mocrotiance with current data prefected in spatial store; process and manage my data, including its disclosure to authorised requests in a mocrotiance with current data prefected in spatial accordance with current data protection spatial and where relevant in redaked, protected format.  Lunderstand and accept that recipients of my information and of the decision on this application may be located outside the current where I reside. In some countries data protection and privacy laws may not be equivalent to those of my country of residence.  Information will be stored securely and retained for the duration of international anti-doping standards. If I believe my information is not used in conformity with my consent. Lean file a complaint with my national data protection regulator. I may have citain rights under applicable laws in reliation to my TUE data, including rights to access and/or correct in accurated and it is ever wish to obtain more information about the use of my health information, to access, rectly, restrict, oppose, delete or revoke this authorisation. I must notly the European Tour Anti-Doping policy.  By signing this form, I expressly consent to the use of my TUE data as set out above.  Player's Signature  Date  Odd/mm/yy,	Yes, for which substance(s)  O Whom?  I approved what duration does the approval to tach copy of TUE Certificate of Approval for so.  PLAYER'S DECLARATION and I.  I request approval to use the medical information to be independent. These independent These independents.	ave Prohibited Substance.  DATA PRIVACY CON  commation set out above is attorn for therapeutic pur appeutic Use Exemption	Date approv.  SENT  accurate. poses only. I auth	In: Not Approved Approved all ends dd/mm/yg,  John State of the state
- shared with other independent medical and/or scientific experts (including the appointed TUE Committee, World Sports Med vib administer TUE information processing) and all messars ystaff moved in the management, review or appear. It is not to TUE decisions if applicable, in accordance with current data protection legislation and where relevant in reducted, protected format.  I understand and accept that recipients of my information and of the decision on this application may be located outside the country where I reside. In some countries data protection and privacy taxes may not be equivalent to those of my country of residence.  Information will be stored securely and retained for the duration of international anti-doping standards. If I believe my information is not used in conformity with my consent, I can title a complaint with my national data protection regulator. I any have certain rights under applicable laws in reliation to my TUE data, including rights to access and/or correct in accurate data.  I understand if I ever wish to obtain more information about the use of my health information, to access, rectly, restrict, oppose, delete or revoke this authorisation, I must notify the European Tour Arti-Doping Adviser includes applications or procedures under the Arti-Doping policy.  By signing this form, I expressly consent to the use of my TUE data as set out above.  Player's Signature  Date  Odd/mm/yy,  Parent's/Guardian's Name  Signature  Date  Odd/mm/yy,	Yes, for which substance(s)  o Whom?  approved what dwarfan does the approval in tatch copy of TUE Certificate of Approval for s  PLAYER'S DECLARATION and ID  I, request approval to use the medical information to the independent. Their professional or contractual confidential.  Loonsent to mylocialins's release.	ame Prohibited Substance.  DATA PRIVACY CON  commation set out above is a papeutic pur papeutic Use Exemption it obligations), appointer go to the above person	Declaid  Date approv.  SENT  accurate. poses only. I author committee and aut of by the European To	Int Not Approved Approved all ends digital and series are series and series are series and series and series and series and series are series and series and series and series are series and series and series and series are series and series and series are series and series a
- shared with other independent medical and/or scientific experts (including the appointed TUE Committee, World Sports Med vib administer TUE information processing) and all messars ystaff moved in the management, review or appear. It is not to TUE decisions if applicable, in accordance with current data protection legislation and where relevant in reducted, protected format.  I understand and accept that recipients of my information and of the decision on this application may be located outside the country where I reside. In some countries data protection and privacy taxes may not be equivalent to those of my country of residence.  Information will be stored securely and retained for the duration of international anti-doping standards. If I believe my information is not used in conformity with my consent, I can title a complaint with my national data protection regulator. I any have certain rights under applicable laws in reliation to my TUE data, including rights to access and/or correct in accurate data.  I understand if I ever wish to obtain more information about the use of my health information, to access, rectly, restrict, oppose, delete or revoke this authorisation, I must notify the European Tour Arti-Doping Adviser includes applications or procedures under the Arti-Doping policy.  By signing this form, I expressly consent to the use of my TUE data as set out above.  Player's Signature  Date  Odd/mm/yy,  Parent's/Guardian's Name  Signature  Date  Odd/mm/yy,	Yes, for which substance(s)  o Whom?  approved what dwarten does the approval in trach copy of TUE Certificate of Approval for s.  PLAYER'S DECLARATION and ID.  I, equest approval to use the medical information to the independent. They professional or contractual confidential Loonsent to mysticanicy's release consider and determine my applications of the confidential undercharden and determine my applications.	ave Prohibited Substance.  DATA PRIVACY CON  commation set out above is altion for therapeutic pur  group to the above person(  to t	Declario  Date approv.  SENT  accurate, poses only. I author committee and aut of by the European To s) any relevant health bo:	nc. Not Approved Approved all ends Approved Appr
I understand and accept that recipients of my information and of the decision on this application may be located outside the country where I reside. In some countries data protection and privacy laws may not be equivalent to those of my country of residence. In some countries data protection and privacy laws may not be equivalent to those of my country of residence in the source of the conformation of the data protection regulator. In the countries were the sold of conformation and the protection regulator. I accurate data in the conformation of the conformation authorities (and the conformation output of the conformation output o	Yes, for which substance(s)  O Whom?  I approved what duration does the approval in tach copy of TUE Certificate of Approval for a PLAYER'S DECLARATION and II.  I request approvial to use the medical information to the medical information to the medical information to the independent Theory of the independent Theory of the independent of the independent and independent and determine my application. I consent to my physician(s) releasing consider and determine my application. I consent to my physician(s) releasing consider and determine my application. I consent to my physician(s) releasing the independent of the i	ave ame Prohibited Substance.  DATA PRIVACY CON  DATA PRIVACY CON  DESCRIPTION OF THE PRIVACY CON  DESCRIPTION OF THE PRIVACY CON  THE PRIVACY	Decision  Date approvi	In: Not Approved Approval al ends dd/mm/yg,  Jorise release of my personal medical thorised officials (who are subject to our.  Ith information deemed necessary to obtation investigations and procedures;
information is not used in conformity with my consent. Loan file a complaint with my national data protection regulator. I may have certain rights under applicable lews in relability to my TUE data, including rights to access and/or correct in accurate data.  Linderstand if ever wish to obtain more information about the use of my health information, to access, rectify, restrict, oppose, delete or revoke this authorisation. I must notly the European Tour Arth-Openig Adviser (included) and the control of the control of the data. I content information may be retained to the purpose of investigations or procedures under the Arth-Doning policy. To consent invocation may be retained for the purpose of investigations or procedures under the Arth-Doning polity.  By signing this form, I expressly consent to the use of my TUE data as set out above.  Player's Signature  Date  dd/mm/yg,  Parent's/Guardian's Name  Signature  Date  dd/mm/yg,	Yes, for which substance(s)  o Whom?  approved bast duration does the approval he tatch copy of TUE Certificate of Approval for tatch copy of TUE Certificate of Approval for so.  PLAYER'S DECLARATION and ID.  i. — certify that the info.  I request approval to use the medical professional or contractual confidential of the contractual confidential concepts and externment may applicate to consider and determinement professional to another memory application of the data. The April Opin decidence to a benefit of request an extensional traction of the data. The April Opin decidence to a benefit of request and a second of the contractual confidential confidentia	ame Prohibited Substance.  DATA PRIVACY CON constitution set out above is prohibited Substance.  DATA PRIVACY CON constitution set out above is prohibited to the Prohibited Substance into the Exemption into displayment of the Substance into corporate of the Substance in the content of potent Dopining and core Medical in and core Medical in and core for which constitution of the Substance in and core for substance in and core for substance in and core Medical in and core for substance in an accordance in a substance	Date approve  SENT  accurate, accurate, accurate and all additional and all and	Inc. Not Approved Approval al ends Approval Approval al ends Approval Approval al ends Approval Approv
oppose, delete or revoke this authorisation. I must notly the European Tour Anti-Doping Adviser (inchestingsonlandening) compared in my medical practioner, in writing of that Start. I understand that information (inchestingsonlandening) compared in the purpose of investigations or procedures under the Anti-Doping policy. By signing this form, I expressly consent to the use of my TUE data as set out above.  Player's Signature  Date dd/mm/yy,  Parent's/Guardian's Name Signature  Date dd/mm/yy,	Yes, for which substance(s)  o Whom?  approved what duration does the approval in titach copy of TUE Certificate of Approval for so PAYER'S DECLARATION and IE  I, equest approval to use the medical information to the independent. These professional or contractula confidential I consent to my hydicanifoly neleasing consider and determine my application. I understands and agree that my TUE request and collection of this data. The Anti-Dopin disclosure to authorised recipients are a shared with other independent Them of the contractulation of the data. The Anti-Dopin disclosure to authorised recipients in a shared with other independent runding which will be a shared to the contractulation of the data. The Anti-Dopin disclosure to authorised recipients in a shared with other independent runding which will be a shared with other independent runding with the contractulation. The disclosure to authorise decipients are contracted format.  I understand and accognit that recipient the country where reside. In some	we warm and the prohibited Substance.  DATA PRIVACY CON commands and solve is a state of the sta	Decision Date approve  SENT  accurate, poses only, I author to prove and anti-doping rule via the anti-doping rule via the anti-doping rule via the anti-doping rule via the approach anti-doping rule via the app	Inc. Not Approved Approved all ends Approved Approved Approved Approved Inc. Approved
Depting points	Yes, for which substance(s)  o Whom?  approved what duration does the approval in tatch copy of TUE Certificate of Approval for so PLAYER'S DECLARATION and ID  I, equest approval to use the medical information to the independent. These professional or contractual confidential. I consent to my hybricanicy's releases consider and determine my application. I understanced and agree that my TUE appears and which existence of the state. The Ards Dipple decision of the state. The Ards Dipple decisions of the Ards Dipple decis	we warm and the prohibited Substance.  DATA PRIVACY CON  command and the substance of the s	Decision Date approv  SENT  accurate, poses only, I author to provide the provided	not Approved Approved all ends Approved Approved all ends Approved Approved all ends Approved
Parent's/Guardian's Name Signature Date dd/mm/yg,	Ness, for which substance(s)  o Whom?  approved what dwasten does the approval in tatch copy of TUE Certificate of Approval for s  PLAYER'S DECLARATION and IE  I,	are Prohibited Substance.  DATA PRIVACY CON  command and a substance of the substance of th	Date approv  SENT  accurate, poses only I author be committee and aut of the committee and aut of the committee and author be call anti-doping rule of the committee and author of the committee and author of the committee author of the committee and a protection legislate for fine decision on the committee and privacy laws a on of international or and privacy laws a on of international or you rule data, include  "You Till data, include the committee and protection legislate and privacy laws a committee and p	Inc. Not Approved Approved all ends Approved App
If applicant is under 10 years of age or has a disability occursoring him to sign this force, a parent or quantism shall sign tenether with or on balacted the	Ness, for which substance(s)  o Whom?  approved what dwasten does the approval in tatch copy of TUE Certificate of Approval for so PLAYER'S DECLARATION and ID  I, equest approval to use the medical information to the independent. These professional or contractular confidential. I consent to my hybricanicy's releasing consider and determine my application. I understanced and agreement my TUE request and collection of the state. The And-Dopin decisions to a state the And-Dopin decisions to a state the And-Dopin decisions are applicated in the state of the state. The And-Dopin decisions in the state of	ame Prohibited Substance.  DATA PRIVACY CON  commation set out above is sition for therapeutic purpose sition for therapeutic purpose sition for therapeutic purpose sition for therapeutic purpose sition for the sition for the sition sition for the sition sition for part of it will only did not consist of pointer sition for part of it will only did not port of it will only did not point of it sition for part of it will only did not point of it sition for part of it sition for pa	Date approvi	Inc. Not Approved Approved all ends Approved App
	Yes, for which substance(s)  o Whom?  approved bast duration does the approval for a provided bast duration does the approval for a provided bast duration does the approval for a provided bast duration	ame Prohibited Substance.  DATA PRIVACY CON  commation set out above is sition for therapeutic purpose sition for therapeutic purpose sition for therapeutic purpose sition for therapeutic purpose sition for the sition for the sition sition for the sition sition for part of it will only did not consist of pointer sition for part of it will only did not port of it will only did not point of it sition for part of it will only did not point of it sition for part of it sition for pa	Date approvi	Inc. Not Approved Approved all ends Approved App
	Ness, for which substance(s)  o Whom?  approved what duration does the approval in titath copy of TUE Certificate of Approval for so.  PLAYER'S DECLARATION and IE  I,	ame Prohibited Substance.  DATA PRIVACY CON  Contains and a story of the story of t	Details approve accurate accurate accurate accurate poses only. I author accurate and author accurate a	no. Not Approved Approved all ends Approved Approved Approved all ends Approved Appr

Evidence confirming the diagnosis must be attached and forwarded with this application.  Evidence confirming the diagnosis must be attached and forwarded with this application.  Farettee of the confirming the diagnosis must be attached and forwarded with this application.  Farettee of the confirming the diagnosis must be attached and forwarded with this application.  Farettee of the confirming the diagnosis of ADHD.  Farettee of the informants used during the diagnosis of ADHD.  Farettee of the informants used during the diagnosis of ADHD.  Farettee of the informants of the partner of the confirming of the partner of the partner of the present informant.  Farettee of the partner of the p	STRICTLY CONF	IDENTIAL		10	TOUR	TOUR TO	JR TOUR
Evidence confirming the diagnosis must be attached and forwarded with this application.  If a permitted medication can be used to treat the medical condition, provide clinical justification for the requested use of the probability of the condition and rationals, with any supporting evidence as to suby a permitted attenuative is not appropriate.  Part of Pa	DIAGNOSIS						
If a permitted medication can be used to less the medical condition, provide clinical justification for the requested use of the morbalish medication and relationals, with any supporting evidence as to ally a permitted alternative is not appropriate.  Part of Part of Part of Part of Part of Part of Persons state:  Part of Part of Part of Part of Part of Part of Persons state:  Present informant:  Part of Part of Part of Part of Part of Part of Persons state:  Present informant:  Part of Part of Part of Part of Part of Persons state:  Present informant:  Part of Part of Part of Part of Part of Part of Persons state:  Present informant:  Part of Part of Part of Part of Part of Persons state:  Present informant:  Part of Part of Part of Part of Part of Part of Persons state:  Present informant:  Part of Part of Part of Part of Part of Part of Persons state:  Present informant:  Part of Part o	Diagnosis with suffi	cient medical informatio	n: see page 4	for details of n	nedical evide	ice required	
If a permitted medication can be used to healt the medical condition, provide clinical justification for the requested use of the control of	Evidence confirming	g the diagnosis must be a	ttached and forw	arded with this	application.		
Present informant: Parent Partner Part							
Present informant: Parent Partner Part							
Present informant: Parent Partner Part							
Present Informant: Parent Parent Parent Porton Other Please state  Parent Paren							
Present informant: Parent Partner Partner Other Please state  Present informant: Parent Partner Partner Partner Please state  Present informant: Parent Partner Partner Partner Please state  Present Partner Partne	If a permitted medication prohibited medication and	can be used to treat the med d rationale, with any supporti	fical condition, p ng evidence as t	ovide clinical ju why a permitte	ustification for ed alternative is	the requested not appropriate	use of the
Present informant: Parent Partner Partner Other Please state  Present informant: Parent Partner Partner Partner Please state  Present informant: Parent Partner Partner Partner Please state  Present Partner Partne	_						
Present informant: Parent Partner Partner Other Please state  Present informant: Parent Partner Partner Partner Please state  Present informant: Parent Partner Partner Partner Please state  Present Partner Partne			- DUD				
Present Informant: Parent Partner Partner Present Informant: Parent Partner Partner Present Informant: Parent Partner				OH	Diagram		
PHYSICIAN'S DECLARATION  certify that the above-resercioned treatment is medically appropriate and that the use of alternative medication not on the incess that the Lurger Processional Registration Note (Modell') and the Company of			_				
Complete all sections on the processor of the condition	Present Informant:	raient	ner 🔲	Other	riease sia	ie.	
Complete all sections on the processor of the condition	DI IVAIAIANIA DEA						
Please complete all sections in English, in capital letters or typing. Please confirming the diagnosis of ADHD In addition to the TUE/ADHD Application For the medical condition to the Tue/ADHD Application for the medical condition to the Tue/ADHD Application for the medical condition to the Tue/ADHD Application for the second as an attachment, or print and fax.  **STRICTLY CONFIDENTIAL**  **GUIDELINES FOR THE COMPLETION OF THE ADHD TUE FORM  **Plants or complete all sections in English, in capital letters or typing. Please confirming the diagnosis of ADHD in secondariow with the transplant directly and an attachment of the secondarion of the secondari			dically appropri	ate and that th	e use of altern	ative medicati	on not on the
Address S  Frofusional Registration No Medical Practitioner:  Date:	prohibited list would be	unsatisfactory for this co	ndition. eview informati	on further.			
Tresponde	Name Medical Speciality		Pro	fessional Regi	stration No		
Figure 1 was described additional information  Vos. No. (note no of pages here)  Signature of Medical Practitioner:  Date: didimmlys.  S. RETROACTIVE APPLICATION  Stris a retroscribe application?  No. Yes. If Yes, date treatment started  Juntation of festiment?  Prevail recommend the started of an acute medical condition was necessary  Advance application on frequent under agriculation (in the prevail of the started)  Dues to offer exceptional circumstances, resultient time or opportunity to submit application prior to sample collection (original).  S. CONFIRMATION OF PREVIOUS APPLICATION FOR TUE/APPROVED TUE IN PLACE  Have your submitted a previous TUE application for the medical condition above?  No. Yes.  Complete collection or the medical condition above?  No. Yes.  STRICTLY CONFIDENTIAL  GUIDELINES FOR THE COMPLETION OF THE ADHD TUE FORM  Please complete a all sections in English, in capital letters or typing. Please note that information submitted in other pages against the string the large to the string the previous submitted and should be readenished. Keep a capy of this againstance should be repaired to the string the previous advanced and the string	Address						
SERIFORCTIVE APPLICATION  Si bits a retroscitive application?  No Yes	Email						
Settis a retroactive application? No Yes If Yes, date treatment started Adminiya, Duration of freshment Peace includar reason for retroactive application.  Agency application of treatment of the administration of the application above?  No Yes Submitted a previous TUE application for the medical condition above?  No Yes Submitted applications will be returned and should be readmitted. Repe a copy of this application for your own records Page 2 of 4  STRICTLY CONFIDENTIAL  SUIDELINES FOR THE COMPLETION OF THE ADD TUE FORM  Please complete all sections is English, in capital letters or typing. Please note that information submitted in other tanguages may take longer to process due to the need for accurate translation. You may complete this form online, save the document and send by email as an attachment with basevage translation. You may complete this form online, save the document and send by email as an attachment with basevage translation. You may complete this form online, save the document and send by email as an attachment with basevage translation. You may complete this form online, save the document and send by email as an attachment with basevage translation. You may complete this form online, save the document and send by email as an attachment with basevage translation. You may complete this form online, save the document and send by email as an attachment with basevage translation. You may complete this form online, save the document and send by email as an attachment with basevage the protection. Original signatures may be translated and the send of the protection of the complete of protec			Yes _				
Strictly Constituent and send on the returned and should be read of a complete applications will be returned and should be read of a complete application will be returned and should be read of the support of the supp	Signature of Medical Pr	actitioner:		Dat	e:	dd/mm/yy,	
Due to other exceptional circumstances, insufficient time or opportunity to submit application programment or treatment of an acute medical condition was necessary Advance application on retroactive applications (ELEHEGENDY use, temporary member registration).  Due to other exceptional circumstances, insufficient time or opportunity to submit application prior to sample collection (explain)	5 RETROACTIVE A	PPLICATION					
Please complete continues will be returned and such continues of the supplication for process of the supplication for the medical condition above?   No   Yes	Is this a retroactive app	lication? No Yes	If Y	es, date treatm	ent started		.dd/mm/yy
Emergency treatment of treatment of an acute medical condition was necessary Advance application not required under applicable intel e.g. p.EMERGENCY, use, temporary member registration).  Due to other exceptional circumstances, insufficient time or opportunity to submit application prior to sample collection (explain).  5. CONFIRMATION OF PREVIOUS APPLICATION FOR TUE/APPROVED TUE IN PLACE  Envery you submitted a previous TUE application for the medical condition above? No Yes  Complete celline, save and send as an attachment, or print and faz.  Submit the completed from by email to authorize the print and faz.  Submit the completed and should be resubmitted. Keep a copy of this application for your own records Prage 2 of 4  STRICTLY CONFIDENTIAL  GUIDELINES FOR THE COMPLETION OF THE ADHO TUE FORM  Please correlets all sections in English, in capital letters or typing. Please note that information submitted in other languages may take longer to process due to the need for accurate tronslation. You may complete his form online, save the document and send by email as an attachment with bassword prosection. Original signatures may be requested later.  Flause complete all sections in English, in capital letters or typing. Please note that information submitted in other languages may take longer to process due to the need for accurate tronslation. You may complete his form online, save the document and send by small as an attachment with bassword prosection. Original signatures may be requested later.  Flause to submit personal information with sufficient safeguards on data transfer shall be at the Player's own real.  In addition to the TUE/ADHO Application Form, supporting medical evidence confirming the diagnosis of ADHO in the process of the proces	Duration of treatment						
Due to other exceptional circumstances, insufficient time or opportunity to submit application prior to sample collection (explain)	Emergency treatmen	t or treatment of an acute me					
STRICTLY CONFIDENTIAL  Complete colline, seve and send as an attachment, or print and fax.  Submit the completed from by amount to submitted. Keep a copy of this application for your own records Page 2 of 4  STRICTLY CONFIDENTIAL  STRICTLY CONFIDENTIAL  GUIDELINES FOR THE COMPLETION OF THE ADHD TUE FORM  Please complete all sections in English, in capital letters or typing. Please note that information submitted in other languages may take longer to process due to the need for accurate translation. You may complete this form online, requested fater.  Failure to submit personal information with sufficient safeguards on data transfer shall be at the Player's own risk.  In addition to the TUE/ADHD Application Form, supporting medical evidence confirming the diagnosis of ADHD in Confidence with DSM-8 criteria MUST be submitted. Where an application is incomplete or ambiguous, European Tour may request the player seeks a second opinion from an experienced psychiatrist recognised by the Tour Chiff Medical Ordiner. The following checklist indicates required evidence or the confidence of the Chiff Medical Ordiner. The following checklist indicates required evidence or the confidence of the Chiff Medical Ordiner. The following checklist indicates required evidence or mitiguous, European Tour may request the player seeks a second opinion from an experienced psychiatrist recognised by the Tour Chiff Medical Ordiner. The following checklist indicates required evidence or the physician who specialises in assessment and treatment of ADHD. The report MUST contain.  Indication of number of years of experience supporting specialist has in assessment and treatment of ADHD. The report MUST contain.  Indication of number of years of experience supporting specialist has in assessment and treatment of ADHD. The report MUST contain.  Indication of number of years of experience supporting specialist has in assessment and treatment of ADHD. The report MUST contain.  Indication of number of years of experience supporting specialist has							
Complete volline, avec and send as an attachment, or print and fac.  Submitted complete volline, avec and send as an attachment, or print and fac.  Submitted the complete applications will be returned and should be resubmitted. Keep a copy of this application for your own records Page 2 of 4  STRICTLY CONFIDENTIAL  SUBJECTIVE CONFIDENTIAL  GUIDELINES FOR THE COMPLETION OF THE ADD THE FORM  Please complete all sections in English, in capital letters or typing. Please note that information submitted in other states of the complete all sections in English, in capital letters or typing. Please note that information submitted in other states are the document and send by email as an attachment and page 2 of 4  Please complete all sections in English, in capital letters or typing. Please note that information submitted in other states are the document and send by email as an attachment and page 3 of 5 of	(explain)	,		,		•	
Complete onfiles, even and and as an attachment, or print and fac. Statushill the complete form by small to authorize page and the complete form by many to authorize page and the complete form by many to authorize page and the complete form by many to authorize page and the complete applications will be returned and should be resultantice. Keep a copy of this application for your own records Page 2 of 4  STRICTLY CONFIDENTIAL  GUIDELINES FOR THE COMPLETION OF THE ADHD TUE FORM  Please complete all sections in English, in capital letters or typing. Please note that information submitted in other languages many bide longer to process due to the need for accurate translation. You may complete this form online, process of the complete page 2 of the complete page 3 of the com	6. CONFIRMATION O	OF PREVIOUS APPLICA	TION FOR TUE	APPROVED	TUE IN PLA	E	
Complete onfiles, even and and as an attachment, or print and fac. Statushill the complete form by small to authorize page and the complete form by many to authorize page and the complete form by many to authorize page and the complete form by many to authorize page and the complete applications will be returned and should be resultantice. Keep a copy of this application for your own records Page 2 of 4  STRICTLY CONFIDENTIAL  GUIDELINES FOR THE COMPLETION OF THE ADHD TUE FORM  Please complete all sections in English, in capital letters or typing. Please note that information submitted in other languages many bide longer to process due to the need for accurate translation. You may complete this form online, process of the complete page 2 of the complete page 3 of the com	Have you submitted a r	revious THE application fo	r the medical c	andition above	2 No 🔲	Voc 🔲	
GUIDELINES FOR THE COMPLETION OF THE ADD TUE FORM  Please complete all sections in English, in capital letters or typing.  Please complete all sections in English, in capital letters or typing.  Please note that information submitted in other languages may take longer to process due to the need for accurate translation. You may complete this form online, may be applied to the process of the pr			raye 2 or 4				
Please complete all sections in English, in capital letters or typing. Please note that information submitted in other languages may take longer to process due to the need for accurate translation. You may complete this form online, as we the document and send by small as an attachment with password protection. Original signatures may be provided to the process of	STRICTLY CON	FIDENTIAL			TOUR I	TOUR TO	UR TOUR
Please complete all sections in English, in capital letters or typing. Please note that information submitted in other languages may take longer to process due to the need for accurate translation. You may complete this form online, as we the document and send by small as an attachment with password protection. Original signatures may be provided to the process of	GUIDI	ELINES FOR THE CO	OMPLETION	OF THE AI	OHD TUE F	ORM	
Fallure to submit personal information with sufficient safeguards on data transfer shall be at the Player's own risk.  In addition to the TUEADHD Application Form, supporting medical evidence confirming the dispnosis of ADHD in accordance with DSAS criteria MUSTs be submitted. Where an application is incomplete or ambiguous, European Tour may request the player seeks a second opinion from an experienced psychiatrist recognised by the Tour Chief Medical Officer. The following checklist indicates required evidence:  1. Psychiatric Assessment Report from a paediatrician, psychiatrist, or other physician who specialises in assessment and treatment of ADHD. The report MUST contain:  1. Indication of number of years of experience supporting specialist has in assessing and treating ADHD, typical supporting of the dispnosite schedule and rating ceale findings.  2. Indication of summary of the dispnosite schedule and rating ceale findings.  3. Attraction play clinical history that includes age without support that presented and any family related history.  4. An outline of the areas where impairment is due to ADHD and not related to other co-occurring mental health or the company of the dispnosite schedule and relating play and the related to other co-occurring mental health or the company of the dispnosite Schedule.  2. Diagnostic Schedule:  2. Diagnostic Schedule:  3. Rating Scales: a copy of the dispnosite schedule conducted to support the diagnosis (DIVA 2.0, CAADID or ACE1)  3. Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISR).  FIRST TIME APPLICATIONS  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  6. Assessment findings from the clinical review meeting richding a summary of current symptoms.  9. Dip to distention of the treatment of the place with the compa							/ :#
Fallure to submit personal information with sufficient safeguards on data transfer shall be at the Player's own risk.  In addition to the TUEADHD Application Form, supporting medical evidence confirming the dispnosis of ADHD in accordance with DSAS criteria MUSTs be submitted. Where an application is incomplete or ambiguous, European Tour may request the player seeks a second opinion from an experienced psychiatrist recognised by the Tour Chief Medical Officer. The following checklist indicates required evidence:  1. Psychiatric Assessment Report from a paediatrician, psychiatrist, or other physician who specialises in assessment and treatment of ADHD. The report MUST contain:  1. Indication of number of years of experience supporting specialist has in assessing and treating ADHD, typical supporting of the dispnosite schedule and rating ceale findings.  2. Indication of summary of the dispnosite schedule and rating ceale findings.  3. Attraction play clinical history that includes age without support that presented and any family related history.  4. An outline of the areas where impairment is due to ADHD and not related to other co-occurring mental health or the company of the dispnosite schedule and relating play and the related to other co-occurring mental health or the company of the dispnosite Schedule.  2. Diagnostic Schedule:  2. Diagnostic Schedule:  3. Rating Scales: a copy of the dispnosite schedule conducted to support the diagnosis (DIVA 2.0, CAADID or ACE1)  3. Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISR).  FIRST TIME APPLICATIONS  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  6. Assessment findings from the clinical review meeting richding a summary of current symptoms.  9. Dip to distention of the treatment of the place with the compa	languages may take save the document	longer to process due to the and send by email as an	e need for accu attachment with	rate translation.	You may cor stection. Orio	nplete this for inal signature	m online, s may be
In addition to the TUE/ADHD Application Form, supporting medical evidence confirming the diagnosis of ADHD in accordance with DSM5-criteria MUST be submitted. Where an application is incomplete or ambiguous, European Tour may request the player seeks a second opinion from an experienced psychiatrist recognised by the Tour Chief Medical Officer. The following checklist indicates required evidence:  1. Psychiatric Assessment Report from a pacidiatrician, psychiatrist, or other physician who specialises in assessment and treatment of ADHD. The report MUST contain:  Indication of number of years of experience supporting specialist has in assessing and treating ADHD. Upscal annual ADHD case load:  3. Burmany of the diagnostic schedule and rating scale finding:  A thorough clinical halony that include age when symptoms first presented and any family related history physical disorders.  A description of the current presentation and treatment plan.  Details of any behaviour landlying chemiques trialled, and drug holidays considered and trialled.  2. Diagnostic Schedule:  a copy of the diagnostic schedule:  3. Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISRS, ASRS, Bartley or CAARS)  FIRST TIME APPLICATIONS  Renewal applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a psychiatric, or other physician who specialises in the teatment of ADHD. The review teeter httlST include:  Description of the treatment effect over the last 12 months, including a report of herefits attituted to the medication and any side	Failure to submit p						
accordance with DSMS criteria MUST be submitted. Where an application is incomplete or ambiguous, European Tour may request the player select a second ophilor from an experienced psychiatris recognised by the Tour Chief Medical Officer. The following chiefs indicates required evidence:  1. Psychiatric Assessment Report from a paediatrical, psychiatrist, or other physician who specialises in assessment and treatment of ADHD. The report MUST contain:  Indication of number of years of experience supporting specialist has in assessing and treating ADHD, typical annual ADHD case load:  Indication of number of years of experience supporting specialist has in assessing and treating ADHD, typical annual ADHD case load:  Summany of the diagnostic schedule and rating sociel findings:  A thiorough clinical history that includes ages when symptoms first presented and any family related history, physical disorders.  A description of the current presentation and treatment plan.  Details of any behaviour and enginglying techniques between the day and drug holidays considered and trialled.  Diagnostic Schedule:  a copy of the diagnostic schedule:  ARRS, Bartley or CAARS)  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications:  **Renewal applications**: a row **TUE/ADHO form** should be completed and submitted to support the renewal request. In addition, a Time review letter MuST in clude:  **Assessment inferiors from the clinical review needing related in the propriate specification and any side effects reported or observed. If there have been periods without medication, a sport on the relation of the medication and any side effects reported or observed. If there have been periods without medication, a	risk.						
Complete cellule.  1. Psychiatric Assessment Report from a pacidiatrical, psychiatric, or other physician who specialises in assessment and treatment of ADHO. The report MUST contain:  1. Indication of number of years of experience supporting specials has in assessing and treating ADHO, typical annual ADHO case load.  2. Indication of number of years of experience supporting specials has in assessing and treating ADHO, typical annual ADHO case load. Instance that the properties of the properti	accordance with DS Tour may request t	M-5 criteria MUST be subn he player seeks a second	itted. Where a opinion from a	n application is n experienced	incomplete o	e diagnosis of r ambiguous, l ecognised by	European the Tour
assessment and treatment of ADHD. The report MUST contain:  Indication of number of years of experience supporting specialist has in assessing and treating ADHD, typical indication of number of years of experience supporting specialist has in assessing and treating ADHD, typical support of the disproposite schedules and rating scale indings  A thorough clinical history that includes age when symptoms first presented and any family related history  An adding of the areas where impairment is due to ADHD and not related to other coccurring mental health or physical disorders  A thorough clinical history that includes age when symptoms first presented and any family related history  Disprostic Schedule:  a copy of the disprostic schedule conducted to support the disprostic (DIVA 2.0, CAADID or ACE+)  3. Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISRS, ASRS, Barkley or CAARS)  FIRST TIME APPLICATIONS  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Letter from a paediatrican, psychiatrics, to other physician who specialises in the treatment of ADHD. The review letter that STS incluse.  Assessment findings from the clinical review meeting including a summary of current symptom is occurring.  Decorption of the treatment effect over the list, 12 months, including a seport to benefits attributed to the medication and any the symptomic experienced during those periods.  Treatment plan for the new 12 months.  For assistance with completion of this form, please contact  Physician Guidelines  With a provision of the release of the policy shall require all evidence outlined as if it is a first-time application.  Complete	Chief Medical Office	r. The following checklist i	ndicates requir	ed evidence:			
annual ADHD case load.  annual ADHD case load.  A thorough chical thatory that includes age when symptoms fair presented and any family related history.  A noutine of the areas where impairment is due to ADHD and not related to other co-occurring mental health or physical disorders.  A description of the current presentation and treatment plan.  Delate of any behavioral modifying techniques traited, and drug holidays considered and trialled.  Dispricts of any behavioral modifying techniques traited, and drug holidays considered and trialled.  Dispricts of the dispricts schedule:  a copy of the dispricts schedule:  a copy of the dispricts schedule conducted to support the dispricts (DIVA 2.0, CAADID or ACE+)  a Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISRS, ASRS, Barkley or CAARS)  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Letter from a paecilatrician, psychiatrist, or other physician who specialises in the treatment of ADHD. The review letter filts of including a summary of current symptoms.  I plo to discription of the treatment effect over the last 12 months, including a report of herefits attributed to the medication and any side effect reported or observed. If there have been periods without medication, a statement should also be provided as to the symptoms experienced during those periods.  Treatment plants are subject to the release of this policy shall require all evidence outlined as if it is a first-time application.  For assistance with completion of this form, please contact.  Physician Guidelines  Michael Verroken (ET Anti Doping Administrator) -44(0)7783-30556.					other physici	an who specia	
Summary of the diagnostic schedule and rating scale findings A through clinical history that includes age when symptoms first presented and any family related history An outline of the areas where impairment is due to ADPRD and not related to other co-occurring mental health or A description of the current presentation and treatment plan Details of any behavioural modifying fechniques trialled, and drug holidays considered and trialled.  Diagnostic Schedule: a copy of the diagnostic schedule conducted to support the diagnosis (DIVA 2.0, CAADID or ACE+) a copy of the diagnostic schedule.  Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISRS, ASRS, Bariley or CAARS)  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Letter from a paediatrician, psychiatrist, or other physician who specialises in the treatment of ADHD. The review letter fitted raing scale results are evidence that opping monitoring of symptom severity is occurring.  Description of the treatment effect over the last 12 monitis, including a sepont to herefits attributed to the medication and any side effects reported or chaptured. If there have been periods without medication, a statement should also be provided as to the previous applications that plant for the release of this policy shall require all evidence outlined as if it is a first-time application.  Teatment plant for the new 12 months.  Michal Vurdence (T. Auti. Dipsip Administration on which the provision and any state effects reported or observed. If there have been periods without medication, a statement should also be provided as to the previous applications made prior to the release of t	<ul> <li>Indication of</li> </ul>	number of years of experier	ice supporting sp	ecialist has in a	ssessing and t	eating ADHD; t	ypical
physical disorders of the current presentation and treatment plan  A description of the current presentation and treatment plan  Distals of any behavioural modifying behavioural and drug holidays considered and trialled.  Behavioural of the disposal control of the control of the control of the control of the disposals (DIVA 2.0, CAADID or ACE+)  Raing Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISRS, ASRS, Barkley or CAARS)  FIRST TIME APPLICATIONS  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Letter from a pacelationian, psychiatrics, or other physician who specialises in the treatment of ADHD. The review letter MIDST include:  Assessment findings from the clinical review meeting including a summary of current symptom of current symptoms of the control of the release of the submitted to the medication and any the symptoms experienced unique to the control of the provided as to the symptoms experienced unique to the summary of the control of the c	annual ADH  • Summary of	D case load. the diagnostic schedule and	rating scale find	ings			
A description of the current presentation and treatment plant Details of any behaviour inaditying charinges trained, and drug holidays considered and trialled.  Diagnostic Schedule: a copy of the diagnosts schedule: a copy of the diagnosts schedule conducted to support the diagnosis (DIVA 2.0, CAADID or ACE+)  Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISRS, ASRS, Barriey or CAARS)  FIRST TIME APPLICATIONS  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Three review letter flutST include.  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Three review letter flutST include.  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Province of the Province of the Complete of the Province of the Province of the Complete of the Province of the Province of the Complete of the Complete of the Province of the Province of the Complete of the C	An outline of physical disc	the areas where impairments there impairments	t is due to ADHD	and not related	to other co-oc	curring mental h	ealth or
2. Diagnostic Schedule: a copy of the diagnostic schedule conducted to support the diagnostic (DIVA 2.0, CAADID or ACE+) a copy of the diagnostic schedule conducted to support the diagnostic (DIVA 2.0, CAADID or ACE+)  Resignations of the conduction of the conduction of the conduction of the disorder (ADHD-RS, AISRS, ASRS, Barkley or CAARS)  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Discussion of the conduction of the physician who specialises in the teatment of ADHD. The review letter MUST include:  - Assessment findings from the clinical review meeting including a summary of current symptoms of the conduction of the provision of the conduction of the cond	<ul> <li>A description</li> </ul>	of the current presentation	and treatment pl nniques trialled. a	an ind drug holidav	s considered a	nd trialled.	
a copy of the diagnostic schedule conducted to support the diagnosis (DIVA 2.0, CAADID or ACE†)  3. Rating Scales: a copy of the rating scale performed to assess severity of the disorder (ADHD-RS, AISRS, ARRS, Barkley or CAARS)  FIRST TIME APPLICATIONS  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Letter from a pacidiatrican, psychiatrist, or other physician who specialises in the treatment of ADHD. The review letter MIDST include:  - Assessment findings from the clinical review meeting including a summary of current symptoms Up to date rating scale results as evidence that ongoing monitoring of symptom severity is occurring Description of the treatment effect over the list 12 months, including a report of benefits attributed to the medication and any the symptoms experienced using those periods who charges are periods who can be symptoms experienced using those periods Treatment plan for the next 12 months. The period without medication, a situation should also be provided as to the symptoms experienced using those periods Treatment plan for the next 12 months. The period without medication, a situation should also be provided as to the symptoms experienced using those periods Treatment plan for the next 12 months. The period without medication, a situation should also be provided as to the symptoms experienced using the separation of the stream should also be provided as to the symptoms experienced using the separation of the stream should as the provided as the annual clinic review meeting. For consistency, the same rating scale used on the provided as the annual clinic review meeting. For consistency, the same rating scale used on the provi	2. Diagnostic	Schedule:					_
ASRS, Barkley or CAARS)  First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewal applications: a rew TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a presentation applications application and applications of the physician who specialises in the teatment of ADHD. The review letter MUST include.  • Assessment findings from the clinical review medicing including a summary of current symptoms and applications are submitted. The review letter MUST include a submitted to the propriets of the propriets and applications are submitted. The review letter fruits are submitted in the propriets and applications are submitted as the propriets are submitted. The review letter fruits are submitted in the symptoms expenienced during those periods.  • Treatment plan for the next 12 months.  **Reting Scales a copy of the rating scale performed at the annual clinic review meeting. For consistency, the same rating scale used in the previous year should continue to be used. Only DSM-based rating scales such as ADHD-RS, AISRS, ASRS, Barkley or CAARS.  **Previous applications made prior to the release of this policy shall require all evidence outlined as if it is a first-time application.  **For assistance with completion of this form, please contact  **Physician Guidelines**  **Michael Verroken (ET Anti-Doping Administrator) -44(07/178) 335559:  **Michael Verroken (ET Anti-Doping Administrator) -44(07/178) 335590:  **Complete ceiline, save and send as an attachment, or arint and fax.	a copy of th	e diagnostic schedule con					
First time applications must include all the above, where the condition is not newly diagnosed, a copy of the most recent specialist review letter must be enclosed to demonstrate that clinical monitoring and evaluation is in place.  RENEWAL APPLICATIONS  Renewed applications: a new TUE/ACHTO form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Letter from a paecilatrician, psychiatrist, or other physician who specialises in the treatment of ADHD. The review letter filts I'include:  - Assessment findings from the clinical review meeting including, a summary of current symptoms Up to determine service the control of the properties of the properti	<ol> <li>Rating Scal ASRS, Bark</li> </ol>	es: a copy of the rating sc ley or CAARS)	ne performed to	assess severi	ty of the disor	aer (ADHD-RS	, AISKS,
Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Latter from a parediatrican, psychiatrist, or other physician who specialises in the treatment of ADHD. The review latter hills? Include:  - Assessment findings from the clinical review meeting including a summary of current symptom.  - Up to date rating scale results as evidence that onzoning monitoring of symptom severity is occurring.  - Description of the treatment effect over the last 12 months, including a report of benefits attributed to the medication and any the symptom experienced during those periods. When the displacement should such be provided as to the symptom experienced during those periods.  - Treatment plan for the next 12 months.  - Treatment plan for the receival periods.  - Treatment pl	FIRST TIME APPLIC	ATIONS					
Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Latter from a parediatrican, psychiatrist, or other physician who specialises in the treatment of ADHD. The review latter hills? Include:  - Assessment findings from the clinical review meeting including a summary of current symptom.  - Up to date rating scale results as evidence that onzoning monitoring of symptom severity is occurring.  - Description of the treatment effect over the last 12 months, including a report of benefits attributed to the medication and any the symptom experienced during those periods. When the displacement should such be provided as to the symptom experienced during those periods.  - Treatment plan for the next 12 months.  - Treatment plan for the receival periods.  - Treatment pl							
Renewal applications: a new TUE/ADHD form should be completed and submitted to support the renewal request. In addition, a Psychiatric Annual Review Letter from a pacidiatrican, psychiatrist, or other physician who specialises in the treatment of ADHD. The review letter MIDST include:  - Assessment findings from the clinical review meeting including a summary of current symptom.  - Up to date rating scale results as evidence that ongoing monitoring of symptom severity is occurring.  - Description of the treatment effect over the last 12 months, notucing a report of benefits attributed to the medication and any the symptom experienced within the last 12 months. Including a report of benefits attributed to the medication and summary of the symptom experienced witing those periods.  - Treatment plan for the next 12 months.  - Treatment plan for the next 12 months.  - Rating Scales: a copy of the rating scale performed at the annual clinic review meeting. For consistency, the same rating scale used on the control of the control o	First time applications	JWXVXXX	where the condit	ion is not newly	diagnosed, a c	opy of the most	recent specialist
Psychiatric Annual Review Letter from a paediatrican, psychiatrist, or other physician who specialises in the treatment of ADH-ID. The review letter fulls! including a summary of current symptoms.  • Assessment findings from the clinical review meeting including a summary of current symptoms.  • Up to date rating scale results as evidence that onpoing monitoring of symptom severity is occurring.  • Description of the treatment effect over the last 12 months, including a report of benefits attributed to the medication and any since effects reported benefits on the three houses be provided as to a several reported benefits on the provided as to a several reported benefits of the provided as to a several reported benefit of the provided as to a several reported benefits of the provided as to a several reported benefit of the provided as to a several reported benefits and the provided as to a several reported benefits and the provided as to a several reported benefits and the provided as to a several results of the provided as the annual clinic review meeting. For consistency, the same rating scale used of the provided results of the provided results are several results as APH-RS, ASRS, Barkley or a several provided continue to be used. Only DSM based rating scales such as APH-RS, ASRS, Barkley or a several provided continue to be used. Only DSM based rating scales such as APH-RS, ASRS, Barkley or a several provided results as a several result as		must include all the above, closed to demonstrate that of	where the condit linical monitoring	ion is not newly and evaluation	diagnosed, a c is in place.	opy of the most	recent specialist
Assessment findings from the claical review meeting including a summay of current symptoms.  In the date rainly scale results as evidence that organic monitoring of symptom severity is cocurring.  Description of the treatment effect over the last 12 months, including a report of henefits attributed to the medication and any side effects reported or observed. If there have been periods without medication, a statement should also be provided as to the symptome experienced during those periods.  Treatment plan for the most 12 months.  Rating Scales: a copy of the rating scale performed at the annual clinic review meeting. For consistency, the same rating scale used in the previous parts should continue to be used. Only DSM-based rating scales such as ADH-D-RS, AISRS, ASRS, Bartley or CAAPS.  For assistance with completion of this form, belease contact  Physician Guidelines  Michele Verroken (ET Ansi Doping Administrator) +44(0)/178/335036.  Michele Verroken (ET Ansi Doping Administrator) +44(0)/178/335036.  Complete ceiline, save and send as an attachment, or arint and fax.	RENEWAL APPLICA	must include all the above, closed to demonstrate that o					
Up to date rating scale results as evidence that ongoing monitoring of symptom severity is occurring     Description of the treatment effect over the last 12 months; including a report of benefits attituded to the medication and any side effects reported or observed. If there have been periods without medication, a statement should also be provided as to the symptoms experienced during those periods.  Rating Scales a copy of the rating scale performed at the annual clinic review meeting. For consistency, the same rating scale used in the previous year should continue to be used. Only DSM-based rating scales such as ADHD-RS, AISRS, ASRS, Baritey or CAANS  Previous applications made prior to the release of this policy shall require all evidence outlined as if it is a first-time application.  For assistance with completion of this form, please contact  Physician Guidelines  Michale Verroken (ET Anti-Doping Administrator) 44(00/TRS 335598):  Michale Verroken (ET Anti-Doping Administrator) 45(00/TRS 335598):  Or by a mail: generating consultant atthus come or michale@sportingintegrity.com  or Dr Andrew Murray ET Chief Medical Officer -44 7791303980 or by email: example to the consultance of	RENEWAL APPLICA	must include all the above, closed to demonstrate that of a new TUE/ADHD form sh	ould be complete	ed and submitted	I to support the	renewal reque	st. In addition, a
side effects reported or observed. If there have been periods without medication, a statement should also be provided as to the symptoms experienced buring those periods.  Rating Scales a copy of the rating scale performed at the annual clinic review meeting. For consistency, the same rating scale used in the previous year should continue to be used. Only DSM-based rating scales such as ADHD-RS, ASRS, ASRS, Bartiey or CANA'S.  Previous applications made prior to the release of this policy shall require all evidence outlined as if it is a first-time application.  For assistance with completion of this form, please contact.  Physician Guidelines  Michael Verroken (ET Anti-Doping Administrator) 44(00/TRS 326598:  Or by a mail: "eversheelingconsultant-tube, come or but and as an attachment, or arint and fax.	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Re The review letter MUST	must include all the above, closed to demonstrate that of ATIONS  a new TUE/ADHD form ship include:	ould be complete cian, psychiatrist	ed and submitted , or other physic	d to support the	renewal reque lises in the trea	st. In addition, a
Treatment plan for the next 12 morths     Rafting Scales a copy of the rating scale performed at the annual clinic review meeting. For consistency, the same rating scale used in the previous pear should continue to be used. Only DSM-based rating scales such as ADHD-RS, AISRS, ASRS, Bartidey or CAARS  Previous applications made prior to the release of this policy shall require all evidence outlined as if it is a first-time application.  For assistance with completion of this form, please contact  Physician Guidelines  Michab Verorkon (ET Anti Doping Administrator) 44(0)(7783-32659):  To Previous application of the control of	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Re The review letter MUST  Assessment fin  Up to date ratio	must include all the above, closed to demonstrate that carries a new TUE/ADHD form showing the term of the clinical revieng scale results as evidence.	ould be complete cian, psychiatrist w meeting includ that ongoing mo	ed and submitted , or other physic ing a summary on initoring of symp	d to support the ian who special of current symptom severity is	renewal reque lises in the trea toms occurring	st. In addition, a tment of ADHD.
in the previous year should continue to be used. Only DSM-based rating scales such as ADHD-RS, ASRS, ASRS, Bartiey or CAANS  Previous applications made prior to the release of this policy shall require all evidence outlined as if it is a first-time application.  For assistance with completion of this form, please contact  Physician Guidelines  Michael Verroken (ET Anti-Doping Administrator) 44(00/TRS 336598:  or by a mail: generating-consultant-tup-cone or michaelegacorting-integrity.com  or by Andrew Murray ET Chief Medical Officer 44 7791303980 or by email: amurray@etghq.com  Complete online, save and send as an attachment, or arrint and fax.	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Re The review letter MUST  Assessment fir Up to date ratir Description of side effects re the symptoms	must include all the above, closed to demonstrate that can be considered to demonstrate that can be considered to the co	ould be complete cian, psychiatrist w meeting includ that ongoing mo last 12 months, i	ed and submitted , or other physic ng a summary o nitoring of symp ncluding a repor	I to support the ian who special of current symptom severity is t of benefits at	renewal reque lises in the trea toms occurring ributed to the n	st. In addition, a treent of ADHD.
Previous applications made prior to the release of this policy shall require all evidence outlined as if it is a first-time application.  For assistance with completion of this form, please contact  Physician Guidelines  Michab Vurnchen (ET Anti Doping Administrator) 44(0)/785-325599.  Michab Vurnchen (ET Anti Doping Administrator) 44(0)/785-325599.  Or by a mail: generateaelineousilate althquo come indebidgeoutlingistratority.com  or Dr Andrew Marray ET Chief Medical Officer 444 7791303990 or by email: amurray@etglata.com  Complete online, save and send as an attachment, or arint and fax.	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Re The review letter MUST  Assessment fit Up to date rule Description of side effects re the symptoms Treatment plan	must include all the above, closed to demonstrate that of  VITONS  a new TUE/ADHD form is  view Letter from a paediatri  include:  andings from the clinical review  g scale results as evidence  the treatment effect over the  control or boserved. If there is  perfect to the perfect  perfect the next 12 months.	ould be complete cian, psychiatrist w meeting includ that orgoing mo last 12 months, have been period	ed and submittee, or other physicing a summary of intoring of sympincluding a report is without medic	I to support the ian who special of current symptom severity is it of benefits at ation, a statem	renewal reque lises in the treat toms occurring ributed to the n ent should also	st. In addition, a tment of ADHD. nedication and any be provided as to
For assistance with completion of this form, please contact  Michele Verroken (ET Anti Doping Administrator) +44(0)7783 326569: or by e-mail: reversolvanisconsulatat etables control or michelestracoministratority.com or by Andrew Marray ET Chief Medical Officer +44 773 130390 or by email: anarray@etable.com  Complete online, save and send as an attachment, or print and fax.	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Re The review letter MUST  Assessment fir Up to date rati Description of iside effects re the symptoms Treatment plan  Rating Scales: a copy.	must include all the above, closed to demonstrate that c XTONS  a new TUE/ADHD form sh view Letter from a paediatri include:  dings from the clinical revier g scale results as evidence the treatment effect over the results are supported to the properties of the performenced during those per formenced during those per from ence 12 months of the rating scale performed	ould be complete cian, psychiatrist w meeting includ that ongoing mo last 12 months, in ave been periodicids	ed and submittee, or other physicing a summary of initioning of symphoduding a reports without medicing creview meeting.	d to support the ian who special of current symptom severity is t of benefits at ation, a statem	renewal reque lises in the trea toms occurring ributed to the n ent should also	st. In addition, a trment of ADHD. edication and any be provided as to
Michab Vuroken (ET. Anti Dopino Administrator) 44(0)7783-326509: or by e mail: generateaefloconsulate aften accome michageoringistratify.com or br Andrew Murray ET Chief Medical Officer 444 7791303980 or by email: amurray@etgha.com  Complete online, save and send as an attachment, or arint and fax,	RENEWAL APPLICAT  Renewal applications: Psychiatric Annual Re The review letter MUST  Assessment fit Up to date rail Side proportion of Side proportion Treatment plan  Rating Scales: a copy in the previous year sho CAARS	must include all the above, closed to demonstrate that or  XTIONS  a new TUE/ADHD form ship with the control of	ould be complete cian, psychiatrist w meeting includ that ongoing mo last 12 months, in anve been period riods	ed and submitted or other physic ng a summary of nitoring of symp ncluding a report is without medic nic review meetiting scales such	if to support the ian who special of current symptom severity is to of benefits at ation, a statem ing. For consist as ADHD-RS	renewal reque lises in the treat toms occurring ributed to the n ent should also tency, the same AISRS, ASRS	st. In addition, a tment of ADHD. sedication and any be provided as to e rating scale used Barkley or
or by a mail: <u>reversion@consultant.ethph.com</u> or <u>michele@sportinginterpty.com</u> or Dr Andrew Murray ET Chief Medical Officer -44 7791303980 or by email: <u>amurray@etghs.com</u> Complete online, save and send as an attachment, or print and fax,	RENEWAL APPLICAT  Renewal applications: Psychiatric Annual Re The review letter MUST  Assessment fit Up to date rail Side proportion of Side proportion Treatment plan  Rating Scales: a copy in the previous year sho CAARS	must include all the above, closed to demonstrate that or  XTIONS  a new TUE/ADHD form ship with the control of	ould be complete cian, psychiatrist w meeting includ that ongoing mo last 12 months, in anve been period riods	ed and submitted or other physic ng a summary of nitoring of symp ncluding a report is without medic nic review meetiting scales such	if to support the ian who special of current symptom severity is to of benefits at ation, a statem ing. For consist as ADHD-RS	renewal reque lises in the treat toms occurring ributed to the n ent should also tency, the same AISRS, ASRS	st. In addition, a tment of ADHD. sedication and any be provided as to e rating scale used Barkley or
Complete online, save and send as an attachment, or print and fax.	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Re- Psychiatric Annual Re- Psychiatric Annual Re- Lip to date and the symptoms Treatment plan Treatment plan Rating Scales: a copy in the previous year she CAARS Previous applications m  For assistance with co	must include all the above, closed to demonstrate that or  XTONS  a new TUE/ADHD form sh  view Letter from a paediatri  include.  didings from the clinical revier  g scale results as evidence  the treatment effect over the  order or observed. If there is  for the next 12 months  of the rating scale performed  uld continue to be used. Or  adde prior to the release of the  implection of this form, please-	ould be complete cian, psychiatrist w meeting includ that ongoing mo last 12 months, in anave been period riods at the annual cli by DSM-based ratios is policy shall re-	ed and submitted or other physic ng a summary of nitoring of symp ncluding a report is without medic nic review meetiting scales such	if to support this ian who special of current symptom severity is to five to find the first ation, a statem ing. For consist as ADHD-RS e outlined as if	renewal reque lises in the trea toms occurring ributed to the n ent should also tency, the same AISRS, ASRS it is a first-time	st. In addition, a tment of ADHD. sedication and any be provided as to e rating scale used Barkley or
Complete online, save and send as an attachment, or print and fax.	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Ren Psychiatric Annual Ren The review letter MUST  Assessment fit Up to date and the symbol of side effects re in the symbol on side effects re in the previous years for CAARS  Previous applications m  For assistance with co	must include all the above, closed to demonstrate that or  NIONS  a new TUE/ADHD form ship of the control of th	ould be complete cian, psychiatrist w meeting includ that ongoing mo last 12 months, i nave been perioc riods lat the annual cli ly DSM-based re is policy shall recontact	ed and submittee or other physic ng a summary or go a summary or swithout medic nic review meeti ting scales such quire all evidenc	d to support this ian who special of current symptom severity is a tof benefits at altition, a statem ing. For consists as ADHD-RS e outlined as if	renewal reque lises in the trea toms occurring ributed to the n ent should also tency, the same AISRS, ASRS it is a first-time	st. In addition, a tment of ADHD. sedication and any be provided as to e rating scale used Barkley or
	RENEWAL APPLICA  Renewal applications: Psychiatric Annual Ren Psychiatric Annual Ren  Assessment fil Up to date file. Sil Description of side effects rep the symptoms Treatment plar  Rating Scales: a copy. The previous years for CANAIS  Previous applications or  For assistance with co	must include all the above, closed to demonstrate that or  NIONS  a new TUE/ADHD form ship of the control of th	ould be complete cian, psychiatrist w meeting includ that ongoing mo last 12 months, i nave been perioc riods lat the annual cli ly DSM-based re is policy shall recontact	ed and submittee or other physic ng a summary or go a summary or swithout medic nic review meeti ting scales such quire all evidenc	d to support this ian who special of current symptom severity is a tof benefits at altition, a statem ing. For consists as ADHD-RS e outlined as if	renewal reque lises in the trea toms occurring ributed to the n ent should also tency, the same AISRS, ASRS it is a first-time	st. In addition, a tment of ADHD. sedication and any be provided as to e rating scale used Barkley or

## MEDICAL FILE - How to Complete - e.g., for GCS joint injections/Anaphylaxis



Additional information for the same medical condition may be added to the Medical File, an audit trail of information is created and may be required as contemporaneous evidence to explain an Adverse Analytical Finding

# **GUIDANCE AND CHECKLISTS FOR TREATING PHYSICIANS**



Cross Referencing of TUE Physician Guidelines with Prohibited Substances and Methods

TUE Physician Guidelines	Prohibited Substances or Methods
Attention Deficit Hyperactivity Disorder (ADHD) <u>TUE Physician Guideline - ADHD</u>	Amphetamine derivatives     Methylphenidate
Adrenal Insufficiency TUE Physician Guideline - Adrenal Insufficiency	<ul><li>Glucocorticoids</li><li>Mineralocorticoids</li></ul>
Anaphylaxis TUE Physician Guideline - Anaphylaxis	Epinephrine (Adrenaline)     Glucocorticoids     Inhaled B2 Agonists
Asthma TUE Physician Guideline - Asthma	Beta 2 Agonists     Glucocorticoids
Cardiovascular Conditions (e.g.: Arterial hypertension) <u>TUE Physician Guideline - Cardiovascular Conditions</u>	Beta-blockers     Diuretics
Diabetes Mellitus TUE Physician Guideline - Diabetes Mellitus	- Insulin
Female Infertility TUE Physician Guideline - Female Infertility	- Clomiphene - letrozole
Growth Hormone Deficiency  - Adults  - Children and Adolescents  TUE Physician Guideline - Growth Hormone Deficiency (Adult)  TUE Physician Guideline - Growth Hormone Deficiency (Child. & Adol.)	- Growth hormone
Inflammatory Bowel Disease TUE Physician Guideline - Inflammatory Bowel Disease	- Glucocorticoids
Intravenous Infusion TUE Physician Guideline - Intravenous Infusion	- IV infusions: Volume greater than 100ml per 12 hours
Intrinsic Sleep Disorders TUE Physician Guideline - Intrinsic Sleep Disorders	Amphetamine derivatives     Methylphenidate     Modafinil
Male Hypogonadism TUE Physician Guideline - Male Hypogonadism	<ul><li>Testosterone</li><li>hCG (human Chorionic Gonadotropin)</li></ul>
Musculoskeletal Conditions TUE Physician Guideline - Musculoskeletal conditions	<ul><li>Glucocorticoids</li><li>Narcotics</li><li>Cannabinoids</li></ul>
Polycystic Ovarian Syndrome (PCOS)  TUE Physician Guideline - PCOS	Clomiphene citrate     letrozole
Sinusitis/Rhinosinusitis TUE Physician Guideline - Sinusitis/Rhinosinusitis	<ul><li>Glucocorticoids</li><li>Pseudoephedrine</li></ul>
Kidney failure and kidney transplantation  TUE Physician Guideline - Renal transplant	- Beta-blockers - Diuretics - Erythropoietin stimulating agents - Glucocorticoids - Hypoxia-inducible factor (HIF) - Prolyl-hydroxylase inhibitors
Pain Management TUE Physician Guideline - Pain Management	<ul><li>Cannabinoids</li><li>Narcotics</li><li>Glucocorticoids</li></ul>
Transgender Athletes TUE Physician Guideline - Transgender Athletes	<ul><li>Spironolactone</li><li>Testosterone</li></ul>

GUIDELINES & CHECKLISTS FOR VARIOUS MEDICAL CONDITIONS				
ADHD Attention Deficit Hyperactivity Disorder)	Adrenal Insufficiency			
<u>Checklist</u>   <u>Guidelines</u>	Checklist   Guidelines			
Anaphylaxis	Asthma			
Checklist   Guidelines	Checklist   Guidelines			
Cardiovascular Conditions Therapeutic Use of Beta-blockers in Athletes	Diabetes Mellitus			
Checklist   Guidelines	<u>Checklist</u>   <u>Guidelines</u>			
Growth Hormone Deficiency in Adults	Inflammatory Bowel Disease			
<u>Checklist</u>   <u>Guidelines</u>	Checklist   Guidelines			
Intravenous Infusion	Intrinsic Sleep Disorders			
<u>Checklist</u>   <u>Guidelines</u>	Checklist   Guidelines			
Male Hypogonadism	Musculoskeletal Conditions			
Checklist   Guidelines	Checklist   Guidelines			
Pain Management	Renal Transplantation			
<u>Checklist</u>   <u>Guidelines</u>	Checklist   Guidelines			
Sinusitis/Rhinosinusitis	Transgender Athletes			
Checklist   Guidelines	Checklist   Guidelines			
Links to Checklist or Guidelines available when resource viewed online				

## **Prescribing Guidance:**

Ensure Player completes Medical File for any prescription of medication. This provides all information in case a TUE application is needed or held as support evidence in response to an Adverse Finding.

If medication contains a Prohibited Substance, check if a TUE is required, or if a Medical File compiled with prescribing Physician is sufficient. For most short-term GCS treatments out of competition, a Medical File is advised, specify the GCS administered. Long term treatments - always complete TUE.

All in-competition treatments involving a Prohibited Substance, complete a TUE Form. This can be processed retroactively if needed. IV infusions are dependent upon location of treatment, ingredients and volume of treatment. A Medical File should be completed which could be submitted with a TUE form if required.

**IV infusions** and/or injections of any substance more than 100 mL per 12 hour period are prohibited at all times, except for those legitimately received in the course of hospital treatment, surgical procedures, or clinical diagnostic investigations.

WARNING: Players and support personnel administering IV infusions which cannot be medically justified commit an anti-doping rule violation (ADRV) whether or not the individual substances are prohibited. IV infusions should be recorded on a Medical File. If administered during a tournament submit a TUE application.

FURTHER INFORMATION on specific permitted and prohibited substances in particular countries is available through websites below:

# IF YOU CANNOT FIND IT, DON'T ASSUME IT'S PERMITTED!

Australia www.globaldro.com/AU/search

Austria www.nada.at /de /medizin /medikamentenabfrage

Czech Republic www.antidoping.cz/zakazane\_prostredky\_leky.php

Denmark www.antidoping.dk /doping /medicin /medicin-app

Canada www.globaldro.com /CA /search

Germany www.nada.de/de/medizin/nadamed/
France www.afld.fr/finder/produits-dopants
Ireland www.eirpharm.com/sports /search

Japan www.globaldro.com/JP/search
New Zealand www.globaldro.com/NZ/search

Norway www. antidoping.no/medisinsk/legemiddelsok

Poland www.leki.antydoping.pl

South Africa www.drugfreesport.org.za/online-medication-check/

Spain https://nodopweb.celad.gob.es
Sweden www.antidoping.se/rodgronalistan
Switzerland www.globaldro.com/CH/search
UK www.globaldro.com/UK/search

USA www.globaldro.com/US/search

REMINDER – SUBSTANCES PROHIBITED IN COMPETITION ARE PROHIBITED AT ALL TIMES IN PROFESSIONAL GOLF